EP0317180B1 - Temperature-controlled active agent dispenser - Google Patents

Temperature-controlled active agent dispenser Download PDF

Info

Publication number
EP0317180B1
EP0317180B1 EP88310610A EP88310610A EP0317180B1 EP 0317180 B1 EP0317180 B1 EP 0317180B1 EP 88310610 A EP88310610 A EP 88310610A EP 88310610 A EP88310610 A EP 88310610A EP 0317180 B1 EP0317180 B1 EP 0317180B1
Authority
EP
European Patent Office
Prior art keywords
agent
polymer
chain crystallizable
temperature
dispenser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP88310610A
Other languages
German (de)
French (fr)
Other versions
EP0317180A1 (en
Inventor
Ray F. Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Landec Labs Inc
Original Assignee
Landec Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landec Labs Inc filed Critical Landec Labs Inc
Priority to AT88310610T priority Critical patent/ATE78703T1/en
Publication of EP0317180A1 publication Critical patent/EP0317180A1/en
Application granted granted Critical
Publication of EP0317180B1 publication Critical patent/EP0317180B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Definitions

  • This invention is in the fields of polymer chemistry and controlled release active agent dispensers. More particularly, it relates to the use of certain side-chain crystallizable polymers as diffusional matrices or membranes in making temperature-controlled active agent dispensers.
  • Controlled-release dispensers that operate on a diffusional mechanism are well known.
  • the agent to be dispensed is dispersed in an agent-permeable polymeric matrix; and the other in which the active agent is contained within a reservoir bounded wholly or partly by an active agent-permeable polymeric membrane.
  • the agent dissolves in the polymer and diffuses through it to the surface of the dispenser and thence to the environment of use.
  • Dispensers of this type have been used for dispensing a variety of active agents to environments of use, such as administration of drugs to animals, including humans, administration of agricultural chemicals to crops or pests, administration of chemicals to water for sanitation purposes, administration of fragrances to mask obnoxious odors, and administration of catalysts to chemical reactions.
  • these prior dispensers have been temperature-insensitive except to the extent that the solubility of the agent in the polymer or the coefficient of diffusion varied with temperature. In the polymers used previously in diffusional-type dispensers this variation typically has not been significant.
  • the present invention uses a type of polymer called a side-chain crystallizable polymer as the diffusional barrier in diffusional-type active agent dispensers.
  • a side-chain crystallizable polymer exhibit permeability to molecules of interest that varies significantly as a function of temperature.
  • temperature-dependent permeation properties permit applicant to make temperature-sensitive dispensers which can be turned on and off by temperature variation or whose rate of release can be increased significantly by a temperature increase.
  • U.S. Patent No. 3,608,549 describes a capsule for administering drugs.
  • the wall of the capsule is made of a drug-permeable nonmelting elastomer such as silicone rubber.
  • the core of the capsule consists of a meltable polymer matrix which contains the drug and a metal coil.
  • the meltable matrix is described as a material which has a solid, crystalline state at low temperature in which it has a low coefficient of diffusion to the drug and a liquid state at higher temperatures in which it has a high coefficient of diffusion to the drug.
  • the metal coil is heated by induction to cause the meltable matrix to become liquid and thus permeable to the drug.
  • the drug diffuses from the device at a rate controlled by its rate of diffusion through the nonmelting capsule wall.
  • the use of a meltable polymer in this patented device is, however, different in several respects from the use of side-chain crystallizable polymers in the present invention.
  • the side-chain crystallizable polymer is in the form of a body that retains its shape and does not become wholly liquid.
  • the side-chain crystallizable polymer is the primary release-rate controlling element in the present invention.
  • dispenser the side-chain crystallizable polymer is not an internal element of the dispenser but instead defines a surface that interfaces with the environment of use.
  • U.S. 4,558,690 describes an anticancer capsule comprising an anti-neoplastic agent encapsulated in a meltable polymer.
  • Polyoctadecyl acrylate a side-chain crystallizable polymer, is used as the meltable polymer.
  • nonionizing radiation is used to locally heat the tumor and melt the capsule wall so that it disintegrates and permits the agent to be released by dissolution.
  • the polymer does not retain its shape and drug release does not occur via diffusion through the polymer.
  • U.S. Patent No. 3,242,051 mentions polyvinyl stearate, another side-chain crystallizable polymer, as a precoating material in a two-step microencapsulation process.
  • Crosslinked side-chain crystallizable polymers are described in J. Polymer Sci.: Macromolecular Reviews (1974) 8:117 and J. Polymer Sci.: Polymer Chemistry Edition (1981) 19:1871-1873. Applicant knows of no use of crosslinked side-chain crystallizable polymers as diffusion matrices.
  • One aspect of the invention is a temperature controlled agent dispenser that provides a reversible, substantial change in agent dispensing rate at a selected temperature comprising a body that maintains its integrity at the selected temperature and is comprised of an agent and a side-chain crystallizable polymer which (i) is in a form that retains its shape and is not free to flow at the selected temperature, (ii) exhibits a phase transition at the selected temperature, (iii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, and (iv) is interposed between the agent and an environment into which the agent is to be dispensed, whereby the rate at which the agent is dispensed to the environment at a temperature equal to or greater than the selected temperature is dependent upon the rate at which the agent diffuses therethrough.
  • One such structure comprises a diffusional matrix comprising a body of (a) a solid support phase and (b) a side-chain crystallizable polymer phase immobilized within the support phase which (i) exhibits a phase transition at a selected temperature and (ii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, wherein there is at least one continuous path through the body that is defined by the side-chain crystallizable polymer phase.
  • Another such structure comprises (a) a continuous agent-permeable polymer membrane and (b) the side-chain crystallizable polymer grafted to the surface of the membrane.
  • a third such structure is a laminated composite comprising (a) a layer of the side-chain crystallizable polymer sandwiched between (b) layers of an agent-permeable polymer wherein the layers of agent permeable polymer are bonded to each other at one or more sites to prevent relative motion therebetween.
  • Another aspect of the invention is a process for making a temperature controlled dispersion-type agent dispenser comprising combining an agent and a side-chain crystallizable monomer, pre-polymer or polymer to form a homogenous mixture thereof, subjecting the mixture to polymerizing or crosslinking conditions at a temperature above the melting point of the side-chain crystallizable polymer to form a dispersion of the agent in crosslinked side-chain crystallizable polymer, and cooling the dispersion to a temperature below said melting point.
  • Active agents include those compositions of matter which when dispensed in their environment of use produce a predetermined, beneficial and useful result. Such agents include for example pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promoters and inhibitors, preservatives, surfactants, disinfectants, catalysts, enzymes, fermentation agents, nutrients, drugs, plant minerals, pheromones, sex sterilants, plant hormones, air purifiers and microorganism attenuators.
  • pesticides herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promoters and inhibitors, preservatives, surfactants, disinfectants, catalysts, enzymes, fermentation agents, nutrients, drugs, plant minerals, pheromones, sex sterilants, plant hormones, air purifiers and microorganism attenu
  • drug as used herein broadly includes physiologically and/or pharmacologically active substances for producing a localized effect at the administration site or a systemic effect at a site remote from the administration site.
  • the backbone of the polymer may be any organic structure (aliphatic or aromatic hydrocarbon, ester, ether or amide) or an inorganic structure (sulfide, phosphazine or silicone).
  • the spacer linkages can be any suitable organic or inorganic unit, for example ester, amide, hydrocarbon, phenyl, ether, or ionic salt (for example a carboxyl-alkyl ammonium or sulphonium or phosphonium ion pair or other known ionic salt pair).
  • the side-chain (defined by S and C) may be aliphatic or aromatic or a combination of aliphatic and aromatic, but must be capable of entering into a crystalline state.
  • linear aliphatic side-chains of at least 10 carbon atoms Common examples are linear aliphatic side-chains of at least 10 carbon atoms, fluorinated aliphatic side-chains of at least 6 carbons, and p-alkyl styrene side-chains wherein the alkyl is of 8 to 24 carbon atoms.
  • the length of the side-chain moiety is usually greater than 5 times the distance between side-chains in the case of acrylates, methacrylates, vinyl esters, acrylamides, methacrylamides, vinyl ethers and alpha olefins.
  • the side chain can be as little as 2 times the length as the distance between branches.
  • the side-chain units should make up greater than 50% of the volume of the polymer, preferably greater than 65% of the volume.
  • Co-monomers added to a side chain polymer usually have an adverse effect on crystallinity. Small amounts of various co-monomers can be tolerated, usually up to 10 to 25 volume percent. In some cases it is desirable to add a small amounts of comonomers, for example cure site monomers such as acrylic acid, glycidal methacrylate, maleic anhydride and amino function monomers.
  • side-chain crystallizable monomers are the acrylate, fluoroacrylate, methacrylate and vinyl ester polymers described in J. Poly. Sci. (1972) 10:3347; J. Poly. Sci. (1972) 10:1657; J. Poly. Sci. (1971) 9:3367; J. Poly. Sci. (1971) 9:3349; J. Poly. Sci. (1971) 9:1835; J.A.C.S. (1954) 76:6280; J. Poly. Sci. (1969) 7:3053; Polymer J. (1985) 17:991, corresponding acrylamides, substituted acrylamide and maleimide polymers (J. Poly. Sci., Poly. Physics Ed.
  • the main properties of the side chain crystallizable polymer that are believed to affect its permeability properties are: melting point, glass transition, crystallinity, crosslink density, and side chain structure. Melting point will be chosen to correlate to the temperature at which release from the device via diffusion through the polymer is desired. For instance, if one desires a device for releasing a given agricultural chemical at 25°C or above, a side chain crystallizable polymer having a melting point of approximately 25°C is chosen.
  • the percent crystallinity of the polymer (below its melting point) will typically be in the range of 10% to 55%, more usually 15% to 50%. In general, the higher the crystallinity, the greater the change in permeability exhibited at phase transition.
  • the crosslink density will typically be greater than about 0.1 to 1.
  • Crosslinking in general decreases permeability at melt. At such crosslink densities, however, the decrease is not sufficient enough to render the permeability of the polymer substantially insensitive to temperature but is sufficient enough to significantly reduce the fluidity of the polymer at temperatures above the melt temperature.
  • the chemical structure of the polymer may vary widely.
  • the permeability of the polymer will typically be at least twofold and more usually at least fivefold higher at or above its melting point than at temperatures below its melting point.
  • the side-chain crystallizable polymer is in a form in which it retains its shape and is not free to flow at its melting temperature (i.e., the temperature/ temperature range at/over which the side chains undergo a phase change from crystalline to amorphous). Otherwise, the polymer would not remain in its intended location (interposed between the agent and the environment) and would be displaced or dispersed elsewhere due to gravitational or other forces.
  • the side-chain crystallizable polymer interfaces directly with the environment (its surface contacts the environment) and would be free at its melt temperature to disperse into the environment.
  • the side-chain crystallizable polymer is crosslinked to a degree such that it becomes viscoelastic at its "melt" temperature but is not so fluid that it readily flows in response to mild forces.
  • crosslinked side chain crystallizable polymer is used to describe side chain crystallizable polymers which are resistant to flow above their side chain melting points. Resistance to flow is obtained by providing sufficient crosslinking density that the material has an elastic modulus above the melting point of the side chains.
  • crosslink density in these materials is described as the number of crosslinks per weight average molecular weight. For example, a polymer having an average molecular weight of 125,000 and having an average of 1 intermolecular crosslink per polymer chain is stated to have a crosslink density of 1.
  • crosslink density greater than about 0.1, preferably greater than 0.5 and most preferably greater than 1. It is not necessary for all of the polymer chains in a material to be crosslinked and a high gel content is not generally necessary unless the application requires great solvent resistance. Generally crosslinking beyond about 10 mole percent is not necessary under normal circumstances and excessive crosslinking can result in decreased crystallinity and impaired performance. In terms of mole percent the crosslinking will normally be in the range of 0.01 percent to 10 mole percent.
  • the crosslinked polymers will normally have a heat of fusion of at least about 20,950 J/Kg (5 cal/g), more usually at least 33,520 J/Kg (8 cal/g).
  • a variety of methods are available to produce crosslinked side chain crystallizable materials for use in controlled release dispensers.
  • a network co-polymer can be prepared by polymerizing a side chain crystallizable monomer and a multifunctional monomer either in one or two steps.
  • a one step process may be used to form a membrane in place, while a two step process is useful where an intermediate processing step is necessary.
  • a variety of multifunctional monomers di, tri or multifunctional acrylic or methacrylic esters, vinyl ethers, esters or amides, isocyanates, aldehydes and epoxides) are known in the art. These multifunctional monomers can be used in a one or two step process depending on the desired result.
  • Ionizing radiation for example beta or gamma radiation, peroxides, silanes or similar cure agents can be used to crosslink a preformed side chain crystallizable polymer with or without added co-monomers.
  • Ionic crosslinks can be formed by for example reacting an acidic polymer site with a di- or tri-valent metal salt or oxide to produce a complex which serves as a crosslink site.
  • organic salts or complexes can be prepared by methods known in the art.
  • Effective crosslinking may also be obtained by physical methods.
  • a block co-polymer of a side chain crystallizable polymer and a second polymer which exhibits a glass transition or melting point higher than the side chain crystallizable polymer may be prepared wherein the entire mass exhibits mechanical stability above the melting point of the side chain crystallizable polymer but below the transition of the second polymer.
  • the side-chain crystallizable polymer is placed within a support such as a microporous membrane, hollow fiber or fabric mesh.
  • the polymer is immobilized by physical entrapment, surface tension, and/or other physical forces.
  • the side-chain crystallizable polymer fills the pores of the membrane or holes in the mesh, thus providing numerous continuous pathways of side-chain crystallizable polymer through the membrane/mesh.
  • the polymer may be placed in the pores/holes by soaking the membrane/mesh in a polymer solution or melt or forcing the polymer solution or melt into the pores/holes under pressure.
  • the membrane/mesh material may be permeable to the agent or impermeable to the agent.
  • agent will permeate through it to the environment of use at a given rate at temperatures below the melt temperature of the side-chain crystallizable polymer. At or above the melt temperature, the agent will permeate through both the membrane/mesh material and the side-chain crystallizable polymer filling the pores, thus providing a higher rate of agent release per unit of surface area. If the membrane/ mesh material is impermeable to the agent, agent will not permeate through the membrane below the melt temperature of the side-chain crystallizable polymer. At or above that temperature, the agent will permeate through the membrane via the continuous pathways of side-chain crystallizable polymer.
  • the membrane or mesh may inherently be made of an electrically conductive material or be coated or contain particles of such a material (e.g., carbon, iron, nickel, copper, aluminum) by which the membrane/mesh may be heated by conduction or induction to cause the side-chain crystallizable material to undergo the desired phase change.
  • a material e.g., carbon, iron, nickel, copper, aluminum
  • materials that enhance radiation absorption may be incorporated into the matrix.
  • the side chain crystallizable polymer be a continuous phase if the second polymer is impermeable to the agent to be delivered, and may be dispersed in the second polymer if the second polymer is essentially permeable to the agent to be delivered.
  • a side chain crystallizable polymer may be immobilized by creating a second polymer phase within or throughout the side chain crystallizable polymer by polymerization and phase separation.
  • a non-crosslinked side chain crystallizable polymer may be heated above its melting point with a second monomer or monomer mixture and the monomer(s) caused to polymerize.
  • a supporting polymer network can be created in situ .
  • the second polymer created be at least partially insoluble in the side chain crystallizable polymer, yet be of a sufficient structure to bind the side chain crystallizable polymer into a stable form above its melting point.
  • a layer of side-chain crystallizable polymer is chemically bonded (grafted) to the surface of an agent-permeable polymer membrane.
  • the chemical bonding immobilizes the side-chain crystallizable polymer and prevents it from migrating out of the path of the agent.
  • the side-chain crystallizable polymer may be grafted to the membrane surface through various functional groups as is known in the art. The particular surface treatments/bonding agents used will vary with the nature of the membrane and the side-chain crystallizable polymer.
  • the side chain crystallizable polymer may also be immobilized by sandwiching it between two agent-permeable polymer membranes that are fused to each other at a plurality of sites so as to prevent relative motion between the membranes when the side-chain crystallizable polymer melts.
  • the fusions may be along continuous lines so as to form a wafer-like structure or be at separated points.
  • FIG. 1 depicts a simple dispersion type device, generally designated 11, which comprises a continuous matrix 12 of crosslinked side-chain crystallizable polymer in which particles of a diffusible active agent 13 are dispersed.
  • a simple dispersion type device generally designated 11
  • the permeability of the polymer to the agent is such that small or negligible amounts of active agent are released from the device.
  • the permeability of the polymer to the agent increases dramatically and active agent dissolves in and diffuses through the polymer to the surface of the device and thence to the environment.
  • a preferred process for making the dispersion-type dispensers of the invention is to combine the active agent and the side-chain crystallizable monomer to form a homogeneous mixture thereof, and subjecting the mixture to polymerizing conditions at a temperature above the melting point of the polymer to form a dispersion of the agent in a crosslinked side-chain crystallizable polymer, and cooling the dispersion to a temperature below said melting point.
  • Figure 2 shows an embodiment of a reservoir-type device, generally designated 16, in the form of a capsule that comprises an active agent containing core 17 and an encapsulating membrane 18 of crosslinked side-chain crystallizable polymer.
  • the core may be neat active agent or a mixture of active agent and a carrier or vehicle therefor.
  • the core will comprise a combination of agent and carrier/vehicle and the amount of agent and its solubility in the carrier/vehicle will be such as to maintain unit activity throughout the intended lifetime of the device.
  • the release of active agent will be substantially constant and at a rate determined by the permeability of the membrane 18 to the agent.
  • the membrane may be made of any of the above described diffusion matrices in which the side-chain crystallizable polymer is immobilized in a support, in a continuous matrix phase at high volume loading, or by chemical bonding to an agent-permeable membrane.
  • materials may be included in the core and/or encapsulating membrane to facilitate or permit the device to be heated by radiation or electrical conduction/induction.
  • Figure 3 illustrates another type embodiment of a reservoir-type device, generally designated 21, in the form of a simple four-layer laminated composite, such as those used for transdermal administration of drugs.
  • the side-chain crystallizable polymer diffusional barrier bounds the surface of the reservoir through which drug passes to the skin.
  • the four layers of the device are: (1) an optional backing layer 22; (2) a drug reservoir layer 23; (3) a side-chain crystallizable polymer diffusion matrix layer 24; and (4) an optional pressure sensitive adhesive layer 25 that forms the basal layer of the device when it is in use.
  • the device Prior to use the device will typically include a fifth removable release liner layer (not shown) that underlies the contact adhesive layer.
  • the general mode of operation of such devices is well known in the medical device art and does not require detailed explanation.
  • the backing provides a protective layer and prevents dissemination of the drug from the upper surface of the reservoir.
  • the reservoir serves as a source of drug and/ or other agents such as skin permeation enhancing agents and may be composed solely of active ingredients or mixtures thereof in carriers.
  • the diffusional matrix serves as the means for regulating the transport of drug from the reservoir to the skin. This matrix may be composed solely of crosslinked side-chain crystallizable polymer or one of the side-chain crystallizable polymer-containing matrices described above. As in the case of the devices of Figures 1 and 2, diffusion of drug through the polymer is small or negligible below the melting point of the polymer and substantial at or above the melting point.
  • the pressure sensitive adhesive serves as a means for affixing the device to the skin. It may also serve as a supplemental reservoir for active ingredient. Other means, such as straps or elastic bands may be used in place of the adhesive to keep the device in contact with the skin.
  • Device 21 may contain means, such as an additional layer of conductive material, or conductive material dispersed in one or more of the layers, for heating the device at will.
  • the device may be heated by placing an external source of heat on the device or by focusing radiation on the device.
  • the device may be cycled through the melting point of the polymer on command, thereby turning the flow of drug from the device to the skin on or off.
  • any pattern of drug release may be achieved.
  • the density of the side-chain crystallizable polymer decreases dramatically with increasing temperature above its melting point.
  • This observation may be used to make dispensers that sink in water or other liquids at temperatures below the melting point and float at higher temperatures.
  • the proportion of agent and polymer are selected such that the dispenser has a density greater than 1.0 g/cm3 below the melting point and a density less than 1.0 g/cm3 above the melting point.
  • Inactive fillers of high or low density may be included in the formulation to adjust the density of the dispenser to a desired value. This feature may be used to make temperature-controlled dispensers that are useful for controlling water-borne pests such as mosquito larvae that inhabit shallow water.
  • a device was fabricated from reservoir and Plexar 1® (Chemplex) with dimensions of 3.8 cm x 7.6 cm x 2.4 mm and having a reservoir surface area of 1.3 cm x 2 cm.
  • a coarse weave polyester mesh 0.15 mm thick was laminated over the reservoir.
  • a thin (approximately 0.13 mm) layer of recrystallized poly(vinyl stearate) (PVS) (Aceto Chemical) was then formed incorporating the mesh as a support.
  • the device was put in distilled water for 16.5 hours with stirring to remove surface NNDMPT.
  • the device was transferred to a clean beaker containing 200 ml of distilled water and maintained at 25°C. Periodically the U.V. absorbance (242 nm) was measured. This test procedure was repeated at 46-47°C and also for a device which was similar but had no PVS control membrane. The observed behavior is shown in Table I.
  • Reservoir material was prepared by mixing 3 g of ferrocene (Aldrich Chemical) with 47 g of Elvax 40® (DuPont). This material was fabricated into a device which had an exposed reservoir surface of 1.5 cm x 3 cm.
  • a solution was prepared containing 97% octadecyl acrylate (Sartomer), 2.5% tri-propyleneglycol diacrylate and 0.5% benzoyl peroxide.
  • Thin films of polyoctadecyl acrylate (PODA) were prepared by casting this solution onto heated glass plates (80-120°C) in a nitrogen atmosphere. The reservoir prepared above was covered with a section of this film and heat sealed. The release kinetics of this device in a 75:25 ethanol:water solution was measured by UV absorbance at 25 and 47°C. Results are given in Table II. Table II Effect of Temperature on Release of Ferrocene By PODA Membrane Temperature Time (min) Relative Rate 25 10,320 1.0 47 160 129.0 25 21,480 0.70
  • Reservoir material was prepared by combining 6.0 g of napthyl methyl carbamate (Carbaryl, Ortho) with 1 gram of acetylene black (a carbon black available from Gulf Canada) and 43 g of Elvax 260. The materials were mixed in a brabender at 100°C and formed into a 15 cm x 15 cm x 2 mm plaque. A sample of reservoir material 2 cm x 2 cm was imbedded in an 2.0 mm sheet of Elvax 260 and one side sealed with Plexar 1 to give a device with 5 cm2 of reservoir material exposed.
  • Carbaryl, Ortho napthyl methyl carbamate
  • acetylene black a carbon black available from Gulf Canada
  • a solution was prepared consisting of 89% octadecyl acrylate, 5% tri-propyleneglycol diacrylate, 5% acrylic acid (Aldrich Chemical) and 1% Irgacure 184.
  • the reservoir portion of the device was coated with 12 drops of solution and the solution cured into a thin coherent film by brief exposure to U.V. irradiation.
  • the completed device was rinsed with warm isopropanol and soaked in ethanol to remove residual monomers.
  • a comparison device was prepared as above except the reservoir surface was covered with a 0.25 mm film of Elvax 40 instead of PODA.
  • the release kinetics were measured in ethanol as before and data is shown in Table IV.
  • Table IV Effect of Temperature on Release of Carbaryl by Elvax 40® Membrane Temperature °C Time (min.) Abs.(280 nm) Rate (abs/min.) 23 40 0.2744 6.86 x 10 e-3 23 65 0.3813 5.87 x 10 e-3 45 30 0.6005 2.00 x 10 e-2
  • Reservoir material was prepared by mixing 44 g of Elvax 250® and 6 g of Surflan®.
  • Surflan is a preemergence herbicide available from Elanco Products Company, division of Eli Lilly and Co., Indianapolis, IN.
  • Devices were prepared by imbedding 2 cm x 2 cm x 1.1 mm portions of reservoir material into a 1.3 mm thick sheet of Elvax 260 which has 2 cm x 2 cm holes cut in it. The resulting devices each had 8 cm2 of exposed reservoir material.
  • the exposed reservoir material was coated with a 0.13 mm thick film of U.V. curable resin prepared by mixing 4.96g of PVS, 0.05g of benzophenone (Aldrich Chemical) and 0.25 g of trimethylolpropane triacrylate (Sartomer). The film was cured by exposure to U.V. radiation.
  • Diazinon® is an organophosphate insecticide available from Ciba-Geigy Corporation, Agricultural Division, Greensboro, NC.
  • a solution was prepared by mixing 1 gram of diazinon and 14 ml of ethanol.
  • Celgard 2500® (Celanese Chemical Co.) was coated with a thin film of U.V. curable PVS (prepared as in the preceding example) and cured via exposure to U.V. radiation.
  • a diffusion cell was prepared by mounting a small piece of coated film into a plastic holder with the aid of a rubber washer. The cell thus formed was filled with the diazinon solution and permeation rates of the membrane were measured as shown in Table VI.
  • Membrane material was prepared by coating and polymerizing a U.V. curable PVS solution in toluene onto Celgard 2500.
  • a stock solution of nicotine was prepared by dissolving 2.0 g of nicotine base in 50 ml of distilled water.
  • the nicotine solution was placed in a diffusion cell as described in the prior example and release properties were measured at 20°C and 41°C as shown in the following table VII.
  • Table VII Permeation of Nicotine Through PVS Membrane Temperature °C Time (min) Rate (abs/min) Relative Rate 20 527 5.1 x 10 x e-5 1 41 45 3.5 x 10 x e-3 67 20 60 6.0 x 10 x e-5 1.2
  • a resistive heating element was prepared as follows.
  • a film obtained from Southwall Technology (Palo Alto, CA) which consisted of a polyester backing layer onto which had been deposited indium tin oxide (ITO) with a top coat of nickel.
  • ITO indium tin oxide
  • a portion of film 3 cm x 7 cm was masked with masking tape and etched in 5 N hydrochloric acid to expose a 1.5 cm x 7 cm portion of the ITO.
  • a thin film of crosslinked poly vinylstearate cured onto the exposed ITO was adherent and translucent when at room temperature.
  • Application of 9 volts to the two nickel electrodes resulting in a current draw of approximately 0.1 amp and the polymer became transparent and tacky after 10 minutes, indicating that it was heated above its melting point. Removal of the power supply caused the polymer to become translucent and hard after about 5 minutes.
  • a nicotine-containing reservoir was prepared by mixing 1 gram of nicotine free base with 9 grams of Ucar Latex 173® (a commercially available emulsion of polyacrylate supplied by Union Carbide Corp. commonly used to prepare pressure sensitive adhesives) and coating this material onto an exposed portion of the ITO and allowing it to dry.
  • Ucar Latex 173® a commercially available emulsion of polyacrylate supplied by Union Carbide Corp. commonly used to prepare pressure sensitive adhesives
  • This reservoir could be prepared in varying thicknesses and was tacky.
  • An overcoat of poly vinylstearate was cured on top to the reservoir and an adhesive coating was applied to that using Ucar Latex 173.
  • the device thus constructed was laminated to a thin (0.1 cm) sheet of foamed polystyrene to prevent heat loss from the backside. Similar insulating films of flexible materials such as foamed polyethylene are commercially available.
  • This device is useful for administering nicotine transdermally.
  • Another temperature-controlled nicotine dispenser was prepared as follows.
  • a sample of Celgard 2500 was sputter coated with nickel to a resistivity of approximately 20 ohms/cm square.
  • a 3 cm x 5 cm portion of this film was etched to remove excess metal and electroded with a conductive epoxy adhesive to provide a porous heating element of 3 square cm area.
  • This composite film was coated with poly octadecylmethacrylate from a toluene solution to allow the polymer to permeate into the porous structure and solvent was allowed to evaporate.
  • This assembly was placed between a 10 ml reservoir containing 4% nicotine (w/w) and another reservoir containing 40 ml of water.
  • the permeation rate of nicotine through the membrane was measured at 19°C over a period of 110 minutes. A potential of 8 volts was applied to the device for a period of time resulting in a current of 0.185 amps. The permeation rate was measured while the device was powered and then the device was turned off. After a period of time the rate was again measured. This process was repeated several times. The release rates are given in Table VIII below.
  • Polymethyltetradecyl siloxane was obtained from Petrarch Systems Inc. 2.4 g of polymer, 0.1 g of t-butyl perbenzoate, 0.1 g of 1-6 hexanediol-diacrylate and 0.15 g of hexadecylacrylate were combined, coated onto Celgard 2500 and cured. Unreacted material was removed by soaking in alcohol for 48 hours.
  • a dispersion-type device (Fig. 1) was prepared by combining 2 g of octadecylacrylate, 1 g of diazinon, 0.1 g of tetradecanediol diacrylate, 0.02 g benzoyl peroxide and 1 drop of N,N dimethyl-p-toludine, pouring the resulting solution into a small vial and curing at 50°C. The resulting solid mass was removed, and a 0.054 gram sample was cooled to 10°C, and rinsed briefly with a solution of ethanol/water (1/1).
  • the matrix device was observed to sink in water at 10°C and to float at 35°C. The effect is fully reversible. Such products which sink in water and do not release at low temperatures but float and release active ingredient at higher temperatures may be useful for controlling waterborne pests such as mosquitoes.
  • Examples 10 and 11 demonstrate the utility of a dispenser with temperature sensitive density and also demonstrate the beneficial effect of preparing a matrix device by mixing an active agent and a side-chain crystallizable polymer or polymer precursor and crosslinking such mixture at a temperature greater than the melting point of the side-chain crystallizable polymer.
  • This example illustrates the use of a nonpolar polyalphaolefin-type side-chain crystallizable polymer as a temperature-controlled diffusional matrix.
  • Polyoctadecene was prepared by polymerizing octadecene with a magnesium chloride supported triethyl aluminum/titanium chloride Zeigler Natta catalyst in isooctane at room temperature. The resulting polymer was precipitated into acetone and dried.
  • a membrane was prepared by dissolving the resulting polymer in toluene and coating the resulting solution onto Celgard 2400®(Celanese Chemical Co.) and dried. Release of technical diazinon through a portion of this film was measured as in Example 5 with the results shown in Table XIII.
  • Table XIII Temperature °C Release Rate ( ⁇ g/cm2 h) 20 19 35 197 40 211 20 13

Description

  • This invention is in the fields of polymer chemistry and controlled release active agent dispensers. More particularly, it relates to the use of certain side-chain crystallizable polymers as diffusional matrices or membranes in making temperature-controlled active agent dispensers.
  • Controlled-release dispensers that operate on a diffusional mechanism are well known. In general, there are two basic types of such devices: one in which the agent to be dispensed is dispersed in an agent-permeable polymeric matrix; and the other in which the active agent is contained within a reservoir bounded wholly or partly by an active agent-permeable polymeric membrane. In both types of devices the agent dissolves in the polymer and diffuses through it to the surface of the dispenser and thence to the environment of use. Dispensers of this type have been used for dispensing a variety of active agents to environments of use, such as administration of drugs to animals, including humans, administration of agricultural chemicals to crops or pests, administration of chemicals to water for sanitation purposes, administration of fragrances to mask obnoxious odors, and administration of catalysts to chemical reactions. In general these prior dispensers have been temperature-insensitive except to the extent that the solubility of the agent in the polymer or the coefficient of diffusion varied with temperature. In the polymers used previously in diffusional-type dispensers this variation typically has not been significant.
  • The present invention uses a type of polymer called a side-chain crystallizable polymer as the diffusional barrier in diffusional-type active agent dispensers. These polymers exhibit permeability to molecules of interest that varies significantly as a function of temperature. These temperature-dependent permeation properties permit applicant to make temperature-sensitive dispensers which can be turned on and off by temperature variation or whose rate of release can be increased significantly by a temperature increase.
  • Several prior art references have involved the use of side-chain crystallizable polymers as elements in active agent dispensers. U.S. Patent No. 3,608,549 describes a capsule for administering drugs. The wall of the capsule is made of a drug-permeable nonmelting elastomer such as silicone rubber. The core of the capsule consists of a meltable polymer matrix which contains the drug and a metal coil. The meltable matrix is described as a material which has a solid, crystalline state at low temperature in which it has a low coefficient of diffusion to the drug and a liquid state at higher temperatures in which it has a high coefficient of diffusion to the drug. The metal coil is heated by induction to cause the meltable matrix to become liquid and thus permeable to the drug. Once this occurs, the drug diffuses from the device at a rate controlled by its rate of diffusion through the nonmelting capsule wall. The patent lists several materials that melt at 40-47°C, including one, poly(stearyl acrylate), that is a side-chain crystallizable polymer. The use of a meltable polymer in this patented device is, however, different in several respects from the use of side-chain crystallizable polymers in the present invention. In the present invention the side-chain crystallizable polymer is in the form of a body that retains its shape and does not become wholly liquid. Also, the side-chain crystallizable polymer is the primary release-rate controlling element in the present invention. Further, in most embodiments of the invention dispenser the side-chain crystallizable polymer is not an internal element of the dispenser but instead defines a surface that interfaces with the environment of use.
  • U.S. 4,558,690 describes an anticancer capsule comprising an anti-neoplastic agent encapsulated in a meltable polymer. Polyoctadecyl acrylate, a side-chain crystallizable polymer, is used as the meltable polymer. Once the composition has been delivered to the tumor, nonionizing radiation is used to locally heat the tumor and melt the capsule wall so that it disintegrates and permits the agent to be released by dissolution. In such a capsule, the polymer does not retain its shape and drug release does not occur via diffusion through the polymer. U.S. Patent No. 3,242,051 mentions polyvinyl stearate, another side-chain crystallizable polymer, as a precoating material in a two-step microencapsulation process.
  • Macromol. Chem. Rapid. Commun. (1986) 7:33-36 describes the permeation of alkanes through membranes composed of a C₁₆ methacrylate polymer (a side chain crystallizable polymer) dispersed in a polycarbonate or coated on a porous polysulfone as a function of temperature. Significant increases in alkane permeability were observed at the melting point of the C₁₆ methacrylate polymer with the membrane composed of the C₁₆ methacrylate polymer coated on a porous polysulfone support. This reference does not relate to temperature-controlled devices for dispensing active agents.
  • Crosslinked side-chain crystallizable polymers are described in J. Polymer Sci.: Macromolecular Reviews (1974) 8:117 and J. Polymer Sci.: Polymer Chemistry Edition (1981) 19:1871-1873. Applicant knows of no use of crosslinked side-chain crystallizable polymers as diffusion matrices.
  • One aspect of the invention is a temperature controlled agent dispenser that provides a reversible, substantial change in agent dispensing rate at a selected temperature comprising a body that maintains its integrity at the selected temperature and is comprised of an agent and a side-chain crystallizable polymer which (i) is in a form that retains its shape and is not free to flow at the selected temperature, (ii) exhibits a phase transition at the selected temperature, (iii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, and (iv) is interposed between the agent and an environment into which the agent is to be dispensed, whereby the rate at which the agent is dispensed to the environment at a temperature equal to or greater than the selected temperature is dependent upon the rate at which the agent diffuses therethrough.
  • Various structures that are useful as temperature-controlled diffusional matrices in regulating the transport of an active agent from a source of said agent to an environment of use for said agent and which include or comprise the above-described side-chain crystallizable polymer in a form in which it is immobilized and thus not free to flow at its melting temperature are another aspect of the invention.
  • One such structure comprises a diffusional matrix comprising a body of (a) a solid support phase and (b) a side-chain crystallizable polymer phase immobilized within the support phase which (i) exhibits a phase transition at a selected temperature and (ii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, wherein there is at least one continuous path through the body that is defined by the side-chain crystallizable polymer phase.
  • Another such structure comprises (a) a continuous agent-permeable polymer membrane and (b) the side-chain crystallizable polymer grafted to the surface of the membrane.
  • A third such structure is a laminated composite comprising (a) a layer of the side-chain crystallizable polymer sandwiched between (b) layers of an agent-permeable polymer wherein the layers of agent permeable polymer are bonded to each other at one or more sites to prevent relative motion therebetween.
  • Another aspect of the invention is a process for making a temperature controlled dispersion-type agent dispenser comprising combining an agent and a side-chain crystallizable monomer, pre-polymer or polymer to form a homogenous mixture thereof, subjecting the mixture to polymerizing or crosslinking conditions at a temperature above the melting point of the side-chain crystallizable polymer to form a dispersion of the agent in crosslinked side-chain crystallizable polymer, and cooling the dispersion to a temperature below said melting point.
  • In the drawings:
    • Figure 1 is an enlarged cross-sectional view of one embodiment of this invention in which active agent is dispersed throughout a matrix of side-chain crystallizable polymer;
    • Figure 2 is an enlarged, cross-sectional view of another embodiment of the invention in which active agent is encapsulated by a membrane of side-chain crystallizable material; and
    • Figure 3 is a cross-sectional view of another embodiment of the invention in which a membrane of side-chain crystallizable material is an element of a laminated composite.
  • "Active agents" as used herein include those compositions of matter which when dispensed in their environment of use produce a predetermined, beneficial and useful result. Such agents include for example pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promoters and inhibitors, preservatives, surfactants, disinfectants, catalysts, enzymes, fermentation agents, nutrients, drugs, plant minerals, pheromones, sex sterilants, plant hormones, air purifiers and microorganism attenuators.
  • The term "drug" as used herein broadly includes physiologically and/or pharmacologically active substances for producing a localized effect at the administration site or a systemic effect at a site remote from the administration site.
  • Side-chain crystallizable polymers, sometimes called "comb-like" polymers are well known and available commercially. These polymers are reviewed in J. Poly. Sci.: Macromol. Rev. (1974) 8:117-253. In general these polymers may be represented by the formula
    Figure imgb0001

    where X is a first monomer unit, Y is a second monomer unit, Z is a backbone atom, S is a spacer unit and C is a crystallizable group. The Mw of C is equal to or greater than twice the sum of the Mws of X, Y and Z. These polymers have a heat of fusion (ΔHf) of at least about 20,950 J/Kg (5 calories/g), preferably at least about 41,900 J/Kg (10 calories/g).
  • The backbone of the polymer (defined by X, Y and Z) may be any organic structure (aliphatic or aromatic hydrocarbon, ester, ether or amide) or an inorganic structure (sulfide, phosphazine or silicone). The spacer linkages can be any suitable organic or inorganic unit, for example ester, amide, hydrocarbon, phenyl, ether, or ionic salt (for example a carboxyl-alkyl ammonium or sulphonium or phosphonium ion pair or other known ionic salt pair). The side-chain (defined by S and C) may be aliphatic or aromatic or a combination of aliphatic and aromatic, but must be capable of entering into a crystalline state. Common examples are linear aliphatic side-chains of at least 10 carbon atoms, fluorinated aliphatic side-chains of at least 6 carbons, and p-alkyl styrene side-chains wherein the alkyl is of 8 to 24 carbon atoms.
  • The length of the side-chain moiety is usually greater than 5 times the distance between side-chains in the case of acrylates, methacrylates, vinyl esters, acrylamides, methacrylamides, vinyl ethers and alpha olefins. In the extreme case of a fluoroacrylate alternate copolymer with butadiene the side chain can be as little as 2 times the length as the distance between branches. In any case the side-chain units should make up greater than 50% of the volume of the polymer, preferably greater than 65% of the volume. Co-monomers added to a side chain polymer usually have an adverse effect on crystallinity. Small amounts of various co-monomers can be tolerated, usually up to 10 to 25 volume percent. In some cases it is desirable to add a small amounts of comonomers, for example cure site monomers such as acrylic acid, glycidal methacrylate, maleic anhydride and amino function monomers.
  • Specific examples of side-chain crystallizable monomers are the acrylate, fluoroacrylate, methacrylate and vinyl ester polymers described in J. Poly. Sci. (1972) 10:3347; J. Poly. Sci. (1972) 10:1657; J. Poly. Sci. (1971) 9:3367; J. Poly. Sci. (1971) 9:3349; J. Poly. Sci. (1971) 9:1835; J.A.C.S. (1954) 76:6280; J. Poly. Sci. (1969) 7:3053; Polymer J. (1985) 17:991, corresponding acrylamides, substituted acrylamide and maleimide polymers (J. Poly. Sci., Poly. Physics Ed. (1980) 18:2197; polyalphaolefin polymers such as those described in J. Poly. Sci.: Macromol. Rev. (1974) 8:117-253 and Macromolecules (1980) 13:12, polyalkylvinylethers, polyalkylethylene oxides such as those described in Macromolecules (1980) 13:15, alkylphosphazene polymers, polyamino acids such as those described in Poly. Sci. USSR (1979) 21:241, Macromolecules (1985) 18:2141, polyisocyanates such as those described in Macromolecules (1979) 12:94, polyurethanes made by reacting amine- or alcohol-containing monomers with long chain alkyl isocyanates, polyesters and polyethers, polysiloxanes and polysilanes such as those described in Macromolecules (1986) 19:611 and p-alkylstyrene polymers such as those described in J.A.C.S. (1953) 75:3326 and J. Poly. Sci. (1962) 60:19.
  • The main properties of the side chain crystallizable polymer that are believed to affect its permeability properties are: melting point, glass transition, crystallinity, crosslink density, and side chain structure. Melting point will be chosen to correlate to the temperature at which release from the device via diffusion through the polymer is desired. For instance, if one desires a device for releasing a given agricultural chemical at 25°C or above, a side chain crystallizable polymer having a melting point of approximately 25°C is chosen. The percent crystallinity of the polymer (below its melting point) will typically be in the range of 10% to 55%, more usually 15% to 50%. In general, the higher the crystallinity, the greater the change in permeability exhibited at phase transition. As indicated below, the crosslink density will typically be greater than about 0.1 to 1. Crosslinking in general decreases permeability at melt. At such crosslink densities, however, the decrease is not sufficient enough to render the permeability of the polymer substantially insensitive to temperature but is sufficient enough to significantly reduce the fluidity of the polymer at temperatures above the melt temperature. As indicated above, the chemical structure of the polymer may vary widely. The permeability of the polymer will typically be at least twofold and more usually at least fivefold higher at or above its melting point than at temperatures below its melting point.
  • For use as a diffusional matrix in accordance with the invention, the side-chain crystallizable polymer is in a form in which it retains its shape and is not free to flow at its melting temperature (i.e., the temperature/ temperature range at/over which the side chains undergo a phase change from crystalline to amorphous). Otherwise, the polymer would not remain in its intended location (interposed between the agent and the environment) and would be displaced or dispersed elsewhere due to gravitational or other forces. In this regard, in many embodiments the side-chain crystallizable polymer interfaces directly with the environment (its surface contacts the environment) and would be free at its melt temperature to disperse into the environment.
  • In one such form, the side-chain crystallizable polymer is crosslinked to a degree such that it becomes viscoelastic at its "melt" temperature but is not so fluid that it readily flows in response to mild forces. Accordingly, the term "crosslinked side chain crystallizable polymer" is used to describe side chain crystallizable polymers which are resistant to flow above their side chain melting points. Resistance to flow is obtained by providing sufficient crosslinking density that the material has an elastic modulus above the melting point of the side chains. Generally, crosslink density in these materials is described as the number of crosslinks per weight average molecular weight. For example, a polymer having an average molecular weight of 125,000 and having an average of 1 intermolecular crosslink per polymer chain is stated to have a crosslink density of 1. In order for a side chain crystallizable polymer to resist flow above the melt it is desirable to have a crosslink density greater than about 0.1, preferably greater than 0.5 and most preferably greater than 1. It is not necessary for all of the polymer chains in a material to be crosslinked and a high gel content is not generally necessary unless the application requires great solvent resistance. Generally crosslinking beyond about 10 mole percent is not necessary under normal circumstances and excessive crosslinking can result in decreased crystallinity and impaired performance. In terms of mole percent the crosslinking will normally be in the range of 0.01 percent to 10 mole percent. The crosslinked polymers will normally have a heat of fusion of at least about 20,950 J/Kg (5 cal/g), more usually at least 33,520 J/Kg (8 cal/g).
  • A variety of methods are available to produce crosslinked side chain crystallizable materials for use in controlled release dispensers. A network co-polymer can be prepared by polymerizing a side chain crystallizable monomer and a multifunctional monomer either in one or two steps. A one step process may be used to form a membrane in place, while a two step process is useful where an intermediate processing step is necessary. A variety of multifunctional monomers (di, tri or multifunctional acrylic or methacrylic esters, vinyl ethers, esters or amides, isocyanates, aldehydes and epoxides) are known in the art. These multifunctional monomers can be used in a one or two step process depending on the desired result. Ionizing radiation, for example beta or gamma radiation, peroxides, silanes or similar cure agents can be used to crosslink a preformed side chain crystallizable polymer with or without added co-monomers. Ionic crosslinks can be formed by for example reacting an acidic polymer site with a di- or tri-valent metal salt or oxide to produce a complex which serves as a crosslink site. Likewise organic salts or complexes can be prepared by methods known in the art.
  • Effective crosslinking may also be obtained by physical methods. For example a block co-polymer of a side chain crystallizable polymer and a second polymer which exhibits a glass transition or melting point higher than the side chain crystallizable polymer may be prepared wherein the entire mass exhibits mechanical stability above the melting point of the side chain crystallizable polymer but below the transition of the second polymer.
  • In another form the side-chain crystallizable polymer is placed within a support such as a microporous membrane, hollow fiber or fabric mesh. In such embodiments the polymer is immobilized by physical entrapment, surface tension, and/or other physical forces. The side-chain crystallizable polymer fills the pores of the membrane or holes in the mesh, thus providing numerous continuous pathways of side-chain crystallizable polymer through the membrane/mesh. The polymer may be placed in the pores/holes by soaking the membrane/mesh in a polymer solution or melt or forcing the polymer solution or melt into the pores/holes under pressure. The membrane/mesh material may be permeable to the agent or impermeable to the agent. If it is permeable to the agent, agent will permeate through it to the environment of use at a given rate at temperatures below the melt temperature of the side-chain crystallizable polymer. At or above the melt temperature, the agent will permeate through both the membrane/mesh material and the side-chain crystallizable polymer filling the pores, thus providing a higher rate of agent release per unit of surface area. If the membrane/ mesh material is impermeable to the agent, agent will not permeate through the membrane below the melt temperature of the side-chain crystallizable polymer. At or above that temperature, the agent will permeate through the membrane via the continuous pathways of side-chain crystallizable polymer.
  • The membrane or mesh may inherently be made of an electrically conductive material or be coated or contain particles of such a material (e.g., carbon, iron, nickel, copper, aluminum) by which the membrane/mesh may be heated by conduction or induction to cause the side-chain crystallizable material to undergo the desired phase change. When the diffusion matrix is intended to be heated by radiation, materials that enhance radiation absorption may be incorporated into the matrix.
  • It is also possible to disperse (blend homogenously) the side-chain crystallizable polymer at high volume loadings (e.g., greater than 20%, usually 50% to 90%) in a continuous or co-continuous phase matrix material that is either permeable or impermeable to the agent. At such high volumes there are sufficient amounts of the dispersed side-chain crystallizable polymer to form continuous paths of side-chain crystallizable polymer through the matrix. In effect then, such dispersions function similarly to the embodiments in which the side-chain crystallizable polymer is suspended within a porous network or mesh. In this regard, it is necessary that the side chain crystallizable polymer be a continuous phase if the second polymer is impermeable to the agent to be delivered, and may be dispersed in the second polymer if the second polymer is essentially permeable to the agent to be delivered.
  • In a similar manner, a side chain crystallizable polymer may be immobilized by creating a second polymer phase within or throughout the side chain crystallizable polymer by polymerization and phase separation. For example, a non-crosslinked side chain crystallizable polymer may be heated above its melting point with a second monomer or monomer mixture and the monomer(s) caused to polymerize. In this case a supporting polymer network can be created in situ. In this case it is desirable that the second polymer created be at least partially insoluble in the side chain crystallizable polymer, yet be of a sufficient structure to bind the side chain crystallizable polymer into a stable form above its melting point.
  • In another form, a layer of side-chain crystallizable polymer is chemically bonded (grafted) to the surface of an agent-permeable polymer membrane. In this instance, the chemical bonding immobilizes the side-chain crystallizable polymer and prevents it from migrating out of the path of the agent. The side-chain crystallizable polymer may be grafted to the membrane surface through various functional groups as is known in the art. The particular surface treatments/bonding agents used will vary with the nature of the membrane and the side-chain crystallizable polymer.
  • The side chain crystallizable polymer may also be immobilized by sandwiching it between two agent-permeable polymer membranes that are fused to each other at a plurality of sites so as to prevent relative motion between the membranes when the side-chain crystallizable polymer melts. The fusions may be along continuous lines so as to form a wafer-like structure or be at separated points. Depending upon the thickness of the side-chain crystallizable layer in such assemblies it may be desirable to make such layer out of crosslinked side-chain crystallizable polymer to prevent the side-chain crystallizable polymer from oozing from the edge of the assembly.
  • The temperature controlled active agent dispensers of the invention may be of the dispersion or reservoir types described above. Figure 1 depicts a simple dispersion type device, generally designated 11, which comprises a continuous matrix 12 of crosslinked side-chain crystallizable polymer in which particles of a diffusible active agent 13 are dispersed. At temperatures below the melting point of the polymer the permeability of the polymer to the agent is such that small or negligible amounts of active agent are released from the device. At temperatures at or above the melting point of the polymer, the permeability of the polymer to the agent increases dramatically and active agent dissolves in and diffuses through the polymer to the surface of the device and thence to the environment. The release rate of agent from such a device will be in accordance with Fick's Law and be proportional to time-1/2. The duration of release will depend upon the configuration of the device and the amount of agent in the device. A preferred process for making the dispersion-type dispensers of the invention is to combine the active agent and the side-chain crystallizable monomer to form a homogeneous mixture thereof, and subjecting the mixture to polymerizing conditions at a temperature above the melting point of the polymer to form a dispersion of the agent in a crosslinked side-chain crystallizable polymer, and cooling the dispersion to a temperature below said melting point.
  • Figure 2 shows an embodiment of a reservoir-type device, generally designated 16, in the form of a capsule that comprises an active agent containing core 17 and an encapsulating membrane 18 of crosslinked side-chain crystallizable polymer. The core may be neat active agent or a mixture of active agent and a carrier or vehicle therefor. Typically, the core will comprise a combination of agent and carrier/vehicle and the amount of agent and its solubility in the carrier/vehicle will be such as to maintain unit activity throughout the intended lifetime of the device. In such embodiments (where unit activity is maintained) the release of active agent will be substantially constant and at a rate determined by the permeability of the membrane 18 to the agent. As in the case of device 11, when the device is maintained at a temperature below the melting point of the polymer, small or negligible release of agent occurs. At or above the melting point, significant release occurs. As an alternative to using a crosslinked side-chain crystallizable membrane, the membrane may be made of any of the above described diffusion matrices in which the side-chain crystallizable polymer is immobilized in a support, in a continuous matrix phase at high volume loading, or by chemical bonding to an agent-permeable membrane.
  • As in the case of device 11, materials may be included in the core and/or encapsulating membrane to facilitate or permit the device to be heated by radiation or electrical conduction/induction.
  • Figure 3 illustrates another type embodiment of a reservoir-type device, generally designated 21, in the form of a simple four-layer laminated composite, such as those used for transdermal administration of drugs. In this embodiment the side-chain crystallizable polymer diffusional barrier bounds the surface of the reservoir through which drug passes to the skin. The four layers of the device are: (1) an optional backing layer 22; (2) a drug reservoir layer 23; (3) a side-chain crystallizable polymer diffusion matrix layer 24; and (4) an optional pressure sensitive adhesive layer 25 that forms the basal layer of the device when it is in use. Prior to use the device will typically include a fifth removable release liner layer (not shown) that underlies the contact adhesive layer. The general mode of operation of such devices is well known in the medical device art and does not require detailed explanation. In this device the backing provides a protective layer and prevents dissemination of the drug from the upper surface of the reservoir. The reservoir serves as a source of drug and/ or other agents such as skin permeation enhancing agents and may be composed solely of active ingredients or mixtures thereof in carriers. The diffusional matrix serves as the means for regulating the transport of drug from the reservoir to the skin. This matrix may be composed solely of crosslinked side-chain crystallizable polymer or one of the side-chain crystallizable polymer-containing matrices described above. As in the case of the devices of Figures 1 and 2, diffusion of drug through the polymer is small or negligible below the melting point of the polymer and substantial at or above the melting point. The pressure sensitive adhesive serves as a means for affixing the device to the skin. It may also serve as a supplemental reservoir for active ingredient. Other means, such as straps or elastic bands may be used in place of the adhesive to keep the device in contact with the skin.
  • Device 21 may contain means, such as an additional layer of conductive material, or conductive material dispersed in one or more of the layers, for heating the device at will. Alternatively, the device may be heated by placing an external source of heat on the device or by focusing radiation on the device. When the device is heated by electrical conduction or induction, the device may be cycled through the melting point of the polymer on command, thereby turning the flow of drug from the device to the skin on or off. Thus, virtually any pattern of drug release may be achieved.
  • It has also been observed that the density of the side-chain crystallizable polymer decreases dramatically with increasing temperature above its melting point. This observation may be used to make dispensers that sink in water or other liquids at temperatures below the melting point and float at higher temperatures. In other words, the proportion of agent and polymer are selected such that the dispenser has a density greater than 1.0 g/cm³ below the melting point and a density less than 1.0 g/cm³ above the melting point. Inactive fillers of high or low density may be included in the formulation to adjust the density of the dispenser to a desired value. This feature may be used to make temperature-controlled dispensers that are useful for controlling water-borne pests such as mosquito larvae that inhabit shallow water.
  • The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner. Unless indicated otherwise, percentages by weight are used in the examples.
  • Example 1
  • Reservoir material was prepared by mixing 7.5g of N,N dimethyl-p-toludine (NNDMPT) (Aldrich Chemical) with 45 g of ethylene-vinyl acetate copolymer (Elvax 260)® (DuPont). Material was mixed thoroughly and allowed to imbibe for 24 hours. Material was then pressed into a 15 cm x 15 cm x 1.6 mm plaque at 120°C.
    ® = Registered trademark
  • A device was fabricated from reservoir and Plexar 1® (Chemplex) with dimensions of 3.8 cm x 7.6 cm x 2.4 mm and having a reservoir surface area of 1.3 cm x 2 cm. A coarse weave polyester mesh 0.15 mm thick was laminated over the reservoir. A thin (approximately 0.13 mm) layer of recrystallized poly(vinyl stearate) (PVS) (Aceto Chemical) was then formed incorporating the mesh as a support. The device was put in distilled water for 16.5 hours with stirring to remove surface NNDMPT. The device was transferred to a clean beaker containing 200 ml of distilled water and maintained at 25°C. Periodically the U.V. absorbance (242 nm) was measured. This test procedure was repeated at 46-47°C and also for a device which was similar but had no PVS control membrane. The observed behavior is shown in Table I.
    Figure imgb0002
  • This set of experiments show that PVS membranes exhibit distinct permeability behavior between 25 and 45°C and that the effect is reversible.
  • Example 2
  • Reservoir material was prepared by mixing 3 g of ferrocene (Aldrich Chemical) with 47 g of Elvax 40® (DuPont). This material was fabricated into a device which had an exposed reservoir surface of 1.5 cm x 3 cm.
  • A solution was prepared containing 97% octadecyl acrylate (Sartomer), 2.5% tri-propyleneglycol diacrylate and 0.5% benzoyl peroxide. Thin films of polyoctadecyl acrylate (PODA) were prepared by casting this solution onto heated glass plates (80-120°C) in a nitrogen atmosphere. The reservoir prepared above was covered with a section of this film and heat sealed. The release kinetics of this device in a 75:25 ethanol:water solution was measured by UV absorbance at 25 and 47°C. Results are given in Table II. Table II
    Effect of Temperature on Release of Ferrocene By PODA Membrane
    Temperature Time (min) Relative Rate
    25 10,320 1.0
    47 160 129.0
    25 21,480 0.70
  • The data show that polyoctadecyl acrylate transports ferrocene more than 100 times faster at 47°C than at 25°C and that this behavior is reversible. The experiments further show that thin films of crosslinked PODA can be laminated and heat sealed onto reservoirs and withstand solvents.
  • Example 3
  • Reservoir material was prepared by combining 6.0 g of napthyl methyl carbamate (Carbaryl, Ortho) with 1 gram of acetylene black (a carbon black available from Gulf Canada) and 43 g of Elvax 260. The materials were mixed in a brabender at 100°C and formed into a 15 cm x 15 cm x 2 mm plaque. A sample of reservoir material 2 cm x 2 cm was imbedded in an 2.0 mm sheet of Elvax 260 and one side sealed with Plexar 1 to give a device with 5 cm² of reservoir material exposed.
  • A solution was prepared consisting of 89% octadecyl acrylate, 5% tri-propyleneglycol diacrylate, 5% acrylic acid (Aldrich Chemical) and 1% Irgacure 184. The reservoir portion of the device was coated with 12 drops of solution and the solution cured into a thin coherent film by brief exposure to U.V. irradiation. The completed device was rinsed with warm isopropanol and soaked in ethanol to remove residual monomers.
  • Release kinetics of this device were measured in 200 ml solutions of ethanol at various temperatures as shown in Table III. Solution Concentrations were determined by measuring the U.V. absorbance at 280 nm as a function of time. In each case the system exhibited nearly zero order kinetics. The rates given are the average over the duration of the experiment. Table III
    Effect of Temperature on Release Kinetics of Carbaryl by PODA Membrane with Cycling
    Temperature °C Time(min.) Abs.(280 nm) Rate(Abs/min.)
    25 107 0.1056 9.87 x 10 e-4
    44 35 0.7653 2.19 x 10 e-2
    30 100 0.1684 1.68 x 10 e-3
    21 150 0.0578 3.85 x 10 e-4
    44 40 0.855 2.14 x 10 e-2
    33 60 0.1926 3.21 x 10 e-3
    40 35 0.5409 1.54 x 10 e-2
    50 40 0.7403 1.85 x 10 e-2
  • These data show that over the temperature range of 21 to 44°C the rate of carbaryl transport by the PODA membrane increases by a factor of 55. Analysis of the data at shorter time intervals showed that the steady state rates showed an even greater change. A similar device with no rate controlling PODA membrane showed less than a two fold increase in rate from 25 to 44°C.
  • A comparison device was prepared as above except the reservoir surface was covered with a 0.25 mm film of Elvax 40 instead of PODA. The release kinetics were measured in ethanol as before and data is shown in Table IV. Table IV
    Effect of Temperature on Release of Carbaryl by Elvax 40® Membrane
    Temperature °C Time (min.) Abs.(280 nm) Rate (abs/min.)
    23 40 0.2744 6.86 x 10 e-3
    23 65 0.3813 5.87 x 10 e-3
    45 30 0.6005 2.00 x 10 e-2
  • This result shows that diffusion of carbaryl through ethylene vinylacetate copolymer is only slightly dependent on temperature over the range of 23 to 45°C. In addition, this experiment shows that PODA is a very good diffusion barrier material at temperatures below its melting point.
  • Example 4
  • Reservoir material was prepared by mixing 44 g of Elvax 250® and 6 g of Surflan®. Surflan is a preemergence herbicide available from Elanco Products Company, division of Eli Lilly and Co., Indianapolis, IN. Devices were prepared by imbedding 2 cm x 2 cm x 1.1 mm portions of reservoir material into a 1.3 mm thick sheet of Elvax 260 which has 2 cm x 2 cm holes cut in it. The resulting devices each had 8 cm² of exposed reservoir material. The exposed reservoir material was coated with a 0.13 mm thick film of U.V. curable resin prepared by mixing 4.96g of PVS, 0.05g of benzophenone (Aldrich Chemical) and 0.25 g of trimethylolpropane triacrylate (Sartomer). The film was cured by exposure to U.V. radiation.
  • Release kinetics in ethanol were determined by U.V. analysis at 24°C, 50°C and 24°C sequentially. The relative rates are given in Table V. Table V
    Effect of Temperature on Release of Surflan® by PVS Membrane
    Temperature °C Time (min) Rate (abs/min) Relative Rate
    24°C 1020 6.01 x 10 e-5 1.0
    50°C 50 1.44 x 10 e-2 239.6
    24°C 1100 8.75 x 10 e-5 1.5
  • Example 5
  • Diazinon® is an organophosphate insecticide available from Ciba-Geigy Corporation, Agricultural Division, Greensboro, NC. A solution was prepared by mixing 1 gram of diazinon and 14 ml of ethanol. Celgard 2500® (Celanese Chemical Co.) was coated with a thin film of U.V. curable PVS (prepared as in the preceding example) and cured via exposure to U.V. radiation. A diffusion cell was prepared by mounting a small piece of coated film into a plastic holder with the aid of a rubber washer. The cell thus formed was filled with the diazinon solution and permeation rates of the membrane were measured as shown in Table VI. Table VI
    Effect of Temperature on Permeation of Diazinon Through PVS Membrane
    Temperature °C Time (min) Rate (abs/min) Relative Rate
    21 1580 2.18 x 10 e-5 1.0
    45 100 3.57 x 10 e-3 163.8
    21 1260 5.16 x 10 e-5 2.4
    43 210 2.48 x 10 e-3 113.8
  • Example 6
  • Membrane material was prepared by coating and polymerizing a U.V. curable PVS solution in toluene onto Celgard 2500. A stock solution of nicotine was prepared by dissolving 2.0 g of nicotine base in 50 ml of distilled water. The nicotine solution was placed in a diffusion cell as described in the prior example and release properties were measured at 20°C and 41°C as shown in the following table VII. Table VII
    Permeation of Nicotine Through PVS Membrane
    Temperature °C Time (min) Rate (abs/min) Relative Rate
    20 527 5.1 x 10 x e-5 1
    41 45 3.5 x 10 x e-3 67
    20 60 6.0 x 10 x e-5 1.2
  • Example 7
  • A resistive heating element was prepared as follows. A film obtained from Southwall Technology (Palo Alto, CA) which consisted of a polyester backing layer onto which had been deposited indium tin oxide (ITO) with a top coat of nickel. A portion of film 3 cm x 7 cm was masked with masking tape and etched in 5 N hydrochloric acid to expose a 1.5 cm x 7 cm portion of the ITO. A thin film of crosslinked poly vinylstearate cured onto the exposed ITO was adherent and translucent when at room temperature. Application of 9 volts to the two nickel electrodes resulting in a current draw of approximately 0.1 amp and the polymer became transparent and tacky after 10 minutes, indicating that it was heated above its melting point. Removal of the power supply caused the polymer to become translucent and hard after about 5 minutes.
  • A nicotine-containing reservoir was prepared by mixing 1 gram of nicotine free base with 9 grams of Ucar Latex 173® (a commercially available emulsion of polyacrylate supplied by Union Carbide Corp. commonly used to prepare pressure sensitive adhesives) and coating this material onto an exposed portion of the ITO and allowing it to dry. This reservoir could be prepared in varying thicknesses and was tacky. An overcoat of poly vinylstearate was cured on top to the reservoir and an adhesive coating was applied to that using Ucar Latex 173. The device thus constructed was laminated to a thin (0.1 cm) sheet of foamed polystyrene to prevent heat loss from the backside. Similar insulating films of flexible materials such as foamed polyethylene are commercially available.
  • This device is useful for administering nicotine transdermally.
  • Example 8
  • Another temperature-controlled nicotine dispenser was prepared as follows. A sample of Celgard 2500 was sputter coated with nickel to a resistivity of approximately 20 ohms/cm square. A 3 cm x 5 cm portion of this film was etched to remove excess metal and electroded with a conductive epoxy adhesive to provide a porous heating element of 3 square cm area. This composite film was coated with poly octadecylmethacrylate from a toluene solution to allow the polymer to permeate into the porous structure and solvent was allowed to evaporate. This assembly was placed between a 10 ml reservoir containing 4% nicotine (w/w) and another reservoir containing 40 ml of water. The permeation rate of nicotine through the membrane was measured at 19°C over a period of 110 minutes. A potential of 8 volts was applied to the device for a period of time resulting in a current of 0.185 amps. The permeation rate was measured while the device was powered and then the device was turned off. After a period of time the rate was again measured. This process was repeated several times. The release rates are given in Table VIII below. Table VIII
    Device State Rate (Abs/Min) Relative Rate
    OFF (110 min.) 0.00029 1.0
    ON (30 min.) 0.0033 11.3
    OFF (180 min.) 0.00043 1.5
    ON (20 min.) 0.0032 11.0
    OFF (55 min.) 0.00033 1.1
    ON (15 min.) 0.0021 7.2
    OFF (90 min.) 0.00037 1.3
  • Example 9
  • Polymethyltetradecyl siloxane was obtained from Petrarch Systems Inc. 2.4 g of polymer, 0.1 g of t-butyl perbenzoate, 0.1 g of 1-6 hexanediol-diacrylate and 0.15 g of hexadecylacrylate were combined, coated onto Celgard 2500 and cured. Unreacted material was removed by soaking in alcohol for 48 hours.
  • A sample of this material was used as a membrane and the rate of diffusion of benzophenone from a 10% (w/v) ethanol volution was determined at a variety of temperatures as shown in Table IX. Table IX
    Diffusion of Benzophenone Through Membrane
    Temperature °C Rate (mg/cm²/h) Relative rate
    5 0.015 1
    10 0.053 3.4
    15 0.70 46
    20 0.98 64
    25 1.30 80
    10 0.13 2.4
    15 0.79 46
  • Example 10
  • A dispersion-type device (Fig. 1) was prepared by combining 2 g of octadecylacrylate, 1 g of diazinon, 0.1 g of tetradecanediol diacrylate, 0.02 g benzoyl peroxide and 1 drop of N,N dimethyl-p-toludine, pouring the resulting solution into a small vial and curing at 50°C. The resulting solid mass was removed, and a 0.054 gram sample was cooled to 10°C, and rinsed briefly with a solution of ethanol/water (1/1). The rate of release of diazinon from the sample of the matrix into water was measured with temperature cycling with the result shown in Table X: Table X
    Temperature °C Time (min.) Release Rate (µg/min.)
    10 4390 0.28
    35 27 21.2
    10 1220 0.08
    35 184 21.3
  • The matrix device was observed to sink in water at 10°C and to float at 35°C. The effect is fully reversible. Such products which sink in water and do not release at low temperatures but float and release active ingredient at higher temperatures may be useful for controlling waterborne pests such as mosquitoes.
  • Example 11
  • 0.6 grams of diazinon was combined with 0.6 grams of hexadecylacrylate acrylic acid co-polymer (95:5) and 0.024 grams of Xama 2® (a multifunctional azaridine available from Virginia Chemical, Portsmouth, Va.) and heated at 50°C for 10 hrs. A 0.019 gram sample was placed into 200 ml of water and release rate of diazinon measured as a function of temperature. The results are given in Table XI. Table XI
    Temperature (°C) Release Rate (µg diazinon/hr)
    10 2.31
    20 4.98
    25 6.99
    30 19.5
    35 36.9
  • This material floated at 35°C and sank at the other temperatures indicated in the Table.
  • In contrast when polyhexadecylacrylate was mixed with diazinon in similar proportions at 60°C, not subjected to crosslinking conditions, and then cooled to 20°C a two phase system resulted which was not useful as a controlled release dispenser.
  • Examples 10 and 11 demonstrate the utility of a dispenser with temperature sensitive density and also demonstrate the beneficial effect of preparing a matrix device by mixing an active agent and a side-chain crystallizable polymer or polymer precursor and crosslinking such mixture at a temperature greater than the melting point of the side-chain crystallizable polymer.
  • Example 12
  • 0.4 grams of hexadecylacrylate maleic anhydride copolymer (90:10 w/w) was combined with 0.6 grams of technical diazinon, and 0.176 grams of Jeffamine T-403 (a multifunctional amine available from Texaco, Bellair, Texas). The resulting mixture was heated at 50°C for 1 hour, cooled and a portion of material placed in water and release rate measured. The results are given in Table XII: Table XII
    Temperature °C Release Rate (ug/mg diazinon/h)
    10 1.2
    30 6.5
    40 10.4
  • Example 13
  • This example illustrates the use of a nonpolar polyalphaolefin-type side-chain crystallizable polymer as a temperature-controlled diffusional matrix. Polyoctadecene was prepared by polymerizing octadecene with a magnesium chloride supported triethyl aluminum/titanium chloride Zeigler Natta catalyst in isooctane at room temperature. The resulting polymer was precipitated into acetone and dried.
  • A membrane was prepared by dissolving the resulting polymer in toluene and coating the resulting solution onto Celgard 2400®(Celanese Chemical Co.) and dried. Release of technical diazinon through a portion of this film was measured as in Example 5 with the results shown in Table XIII. Table XIII
    Temperature °C Release Rate (µg/cm² h)
    20 19
    35 197
    40 211
    20 13
  • Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in polymer chemistry controlled release devices or related fields are intended to be within the scope of the following claims.

Claims (19)

  1. A temperature controlled active agent dispenser that provides a reversible, substantial change in agent dispensing rate at a selected temperature comprising a body that maintains its integrity at the selected temperature and is comprised of an agent and a side-chain crystallizable polymer which (i) is in a form that retains its shape and is not free to flow at the selected temperature, (ii) exhibits a phase transition at the selected temperature, (iii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, and (iv) is interposed between the agent and an environment into which the agent is to be dispensed whereby the rate at which the agent is dispensed to the environment at a temperature equal to or greater than the selected temperature is dependent upon the rate at which the agent diffuses therethrough.
  2. The dispenser of claim 1 wherein the side-chain crystallizable polymer defines at least a part of the exterior surface of the device.
  3. The dispenser of claim 1 or 2 wherein said form constitutes a crosslinked side-chain crystallizable polymer that is a viscoelastic solid at the selected temperature.
  4. The dispenser of claim 3 wherein the body comprises a dispersion of the agent in the crosslinked side-chain crystallizable polymer.
  5. The dispenser of claim 3 wherein the body comprises a core of the agent bounded wholly or partly by a membrane of the crosslinked side-chain crystallizable polymer.
  6. The dispenser of claim 5 wherein the core comprises a mixture of the agent and a vehicle or carrier therefor.
  7. The dispenser of claim 1, 2 or 3 wherein the body comprises a laminated composite one of the laminas of which is composed of a dispersion of the agent in the side-chain crystallizable polymer.
  8. The dispenser of claim 1, 2 or 3 wherein the body comprises a laminated composite one of the laminas of which is composed of a mixture of the agent and a vehicle or carrier therefor and another of the laminas is composed of the side-chain crystallizable polymer.
  9. The dispenser of claim 7 or 8 wherein the agent is a drug and the dispenser is for administering the drug transdermally.
  10. The dispenser of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 including means for heating the dispenser by conduction, induction or radiation.
  11. The dispenser of claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein the body has a density greater than 1 g/ml at temperatures below the selected temperature and a density less than 1 g/ml at temperatures above the selected temperature.
  12. A temperature-controlled diffusional matrix for regulating transport of an active agent from a source of the agent to an environment of use for the agent comprising a body of (a) a solid support phase and (b) a side-chain crystallizable polymer phase which (i) exhibits a phase transition at a selected temperature and (ii) has substantially greater permeability to the agent at temperatures equal to or greater than the selected temperature than at temperatures below the selected temperature, wherein there is at least one continuous path through the body that is defined by the side-chain crystallizable polymer phase and the side-chain crystallizable polymer is immobilized.
  13. The diffusional matrix of claim 12 wherein the solid support phase is a microporous membrane and the side-chain crystallizable polymer is within the pores of the membrane.
  14. The diffusional matrix of claim 12 wherein the solid support is a mesh and the side chain crystallizable polymer is within the holes of the mesh.
  15. The diffusional matrix of claim 12 wherein the solid support phase is continuous and the side-chain crystallizable polymer is dispersed in the solid support phase at a volume loading above 20%.
  16. The diffusional matrix of claim 12, 13, 14 or 15 including means for heating the matrix by conduction, induction or radiation.
  17. The diffusion matrix of claim 12 wherein the solid support is an agent-permeable polymer membrane and wherein a layer of side-chain crystallizable polymer is grafted to the surface of the membrane.
  18. The diffusion matrix of claim 12 wherein the solid support comprises layers of an agent-permeable polymer membrane and wherein a layer of side-chain crystallizable polymer is sandwiched between the layers of the membrane, and all the layers are bonded to each other to prevent relative motion therebetween.
  19. A process for making a temperature controlled dispersion-type agent dispenser according to any one of claims 1 to 11 comprising combining an agent and a side-chain crystallizable monomer, pre-polymer or polymer to form a homogenous mixture thereof, subjecting the mixture to polymerizing or crosslinking conditions at a temperature above the melting point of the side-chain crystallizable polymer to form a dispersion of the agent in crosslinked side-chain crystallizable polymer, and cooling the dispersion to a temperature below said melting point.
EP88310610A 1987-11-13 1988-11-10 Temperature-controlled active agent dispenser Expired - Lifetime EP0317180B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT88310610T ATE78703T1 (en) 1987-11-13 1988-11-10 TEMPERATURE CONTROLLED DISPENSER.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/120,399 US4830855A (en) 1987-11-13 1987-11-13 Temperature-controlled active agent dispenser
US120399 1987-11-13

Publications (2)

Publication Number Publication Date
EP0317180A1 EP0317180A1 (en) 1989-05-24
EP0317180B1 true EP0317180B1 (en) 1992-07-29

Family

ID=22390019

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88310610A Expired - Lifetime EP0317180B1 (en) 1987-11-13 1988-11-10 Temperature-controlled active agent dispenser

Country Status (13)

Country Link
US (1) US4830855A (en)
EP (1) EP0317180B1 (en)
JP (1) JPH0618788B2 (en)
KR (1) KR0131598B1 (en)
AR (1) AR244087A1 (en)
AT (1) ATE78703T1 (en)
DE (1) DE3873275T2 (en)
ES (1) ES2034260T3 (en)
IL (1) IL88315A (en)
NZ (1) NZ226921A (en)
PH (1) PH24852A (en)
WO (1) WO1989004648A1 (en)
ZA (1) ZA888421B (en)

Families Citing this family (579)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01122037U (en) * 1988-02-12 1989-08-18
US5254354A (en) * 1990-12-07 1993-10-19 Landec Corporation Food package comprised of polymer with thermally responsive permeability
AU5549590A (en) * 1989-05-11 1990-11-29 Landec Labs, Inc. Temperature-activated adhesive assemblies
EP0497919B1 (en) * 1989-10-23 1996-12-11 THERATECH, INC. (a Delaware Corporation) Iontophoresis device using a rate-controlling membrane
US5120349A (en) * 1990-12-07 1992-06-09 Landec Labs, Inc. Microcapsule having temperature-dependent permeability profile
EP0560901B1 (en) * 1990-12-07 1997-05-14 Landec Labs. Inc. Packages with temparature-sensitive permeability for foods and flowers
US5665822A (en) * 1991-10-07 1997-09-09 Landec Corporation Thermoplastic Elastomers
CA2060113A1 (en) * 1991-02-01 1992-08-02 Agis Kydonieus Temperature activated controlled release device
US5580573A (en) * 1991-02-01 1996-12-03 E. R. Squibb And Sons, Inc. Temperature activated controlled release
US5752926A (en) * 1992-04-29 1998-05-19 Landec Corporation Orthopedic casts
CA2134219A1 (en) * 1992-04-29 1993-11-11 Ray F. Stewart Orthopedic casts
NZ248977A (en) * 1992-11-09 1995-06-27 Squibb & Sons Inc Pressure-sensitive adhesive comprising a polyurethane having excess hydroxyl functionality; medical articles comprising a layer of such adhesive
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US6255367B1 (en) 1995-03-07 2001-07-03 Landec Corporation Polymeric modifying agents
US6831116B2 (en) * 1995-03-07 2004-12-14 Landec Corporation Polymeric modifying agents
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6756053B2 (en) * 1995-07-28 2004-06-29 Zars, Inc. Controlled heat induced rapid delivery of pharmaceuticals from skin depot
US6284266B1 (en) 1995-07-28 2001-09-04 Zars, Inc. Methods and apparatus for improved administration of fentanyl and sufentanil
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US5658583A (en) * 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
US5730721A (en) * 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US5698250A (en) 1996-04-03 1997-12-16 Tenneco Packaging Inc. Modifield atmosphere package for cut of raw meat
US6926846B1 (en) 1996-08-08 2005-08-09 Pactiv Corporation Methods of using an oxygen scavenger
US5928560A (en) * 1996-08-08 1999-07-27 Tenneco Packaging Inc. Oxygen scavenger accelerator
US6395195B1 (en) 1996-08-08 2002-05-28 Pactiv Corporation Oxygen scavenger accelerator
AU3212199A (en) * 1998-03-31 1999-10-18 Scimed Life Systems, Inc. Temperature controlled solute delivery system
US6054153A (en) * 1998-04-03 2000-04-25 Tenneco Packaging Inc. Modified atmosphere package with accelerated reduction of oxygen level in meat compartment
US6955819B2 (en) 1998-09-29 2005-10-18 Zars, Inc. Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances
US6726673B1 (en) 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
US6231905B1 (en) 1998-10-08 2001-05-15 Delduca Gary R. System and method of making a modified atmosphere package comprising an activated oxygen scavenger for packaging meat
CA2367571A1 (en) * 1999-03-17 2000-09-21 Foster-Miller, Inc. Responsive gels and methods of use thereof
DE19923427A1 (en) * 1999-05-21 2000-11-23 Lohmann Therapie Syst Lts Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow
US6321509B1 (en) 1999-06-11 2001-11-27 Pactiv Corporation Method and apparatus for inserting an oxygen scavenger into a modified atmosphere package
US6453648B1 (en) 1999-07-06 2002-09-24 Zars, Inc. Method for manufacturing a heat generating apparatus
BR0005598B1 (en) * 1999-09-16 2013-03-19 Method to protect a growing plant against creeping insects.
US7101928B1 (en) * 1999-09-17 2006-09-05 Landec Corporation Polymeric thickeners for oil-containing compositions
WO2001064151A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Methods and apparatus for controlled heat to regulate transdermal delivery of medical substances
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US20030054073A1 (en) * 2001-07-25 2003-03-20 Delduca Gary R. Modified atmosphere packages and methods for making the same
US20030054074A1 (en) * 2001-07-25 2003-03-20 Delduca Gary R. Modified atomsphere packages and methods for making the same
US6812314B2 (en) * 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
AU2003213459A1 (en) * 2002-03-14 2003-09-22 Nippon Shinyaku Co., Ltd External medicine for wounds
US7261734B2 (en) * 2002-04-23 2007-08-28 Boston Scientific Scimed, Inc. Resorption-controllable medical implants
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
BR0303954A (en) * 2002-10-10 2004-09-08 Int Flavors & Fragrances Inc Composition, fragrance, method for dividing an olfactory effective amount of fragrance into a non-rinse and non-rinse product
US7585824B2 (en) 2002-10-10 2009-09-08 International Flavors & Fragrances Inc. Encapsulated fragrance chemicals
US8709038B2 (en) * 2002-12-20 2014-04-29 Boston Scientific Scimed, Inc. Puncture hole sealing device
CA2513402A1 (en) * 2003-02-07 2004-08-19 Walter Mueller Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof
DE10315640A1 (en) * 2003-04-04 2004-10-14 Ignatov, Konstantin Process for the controlled release of components into a solution
US20070084897A1 (en) 2003-05-20 2007-04-19 Shelton Frederick E Iv Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism
US9060770B2 (en) 2003-05-20 2015-06-23 Ethicon Endo-Surgery, Inc. Robotically-driven surgical instrument with E-beam driver
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
WO2005003821A2 (en) * 2003-06-03 2005-01-13 Bay Materials Llc Phase change sensor
NL1023720C2 (en) * 2003-06-23 2004-12-28 Univ Eindhoven Tech Method for changing the transport properties of a material, method for releasing a drug from an implant, as well as implant with drug.
US20050112152A1 (en) * 2003-11-20 2005-05-26 Popplewell Lewis M. Encapsulated materials
US20050113282A1 (en) * 2003-11-20 2005-05-26 Parekh Prabodh P. Melamine-formaldehyde microcapsule slurries for fabric article freshening
US7105064B2 (en) 2003-11-20 2006-09-12 International Flavors & Fragrances Inc. Particulate fragrance deposition on surfaces and malodour elimination from surfaces
US7192991B2 (en) * 2003-11-26 2007-03-20 3M Innovative Properties Company Cationically curable composition
US20050226900A1 (en) * 2004-04-13 2005-10-13 Winton Brooks Clint D Skin and hair treatment composition and process for using same resulting in controllably-releasable fragrance and/or malodour counteractant evolution
US11890012B2 (en) 2004-07-28 2024-02-06 Cilag Gmbh International Staple cartridge comprising cartridge body and attached support
US8215531B2 (en) 2004-07-28 2012-07-10 Ethicon Endo-Surgery, Inc. Surgical stapling instrument having a medical substance dispenser
US7594594B2 (en) 2004-11-17 2009-09-29 International Flavors & Fragrances Inc. Multi-compartment storage and delivery containers and delivery system for microencapsulated fragrances
MX2007008258A (en) 2005-01-10 2007-08-22 Avery Dennison Corp Removable curl labels.
US20070207174A1 (en) * 2005-05-06 2007-09-06 Pluyter Johan G L Encapsulated fragrance materials and methods for making same
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
US10159482B2 (en) 2005-08-31 2018-12-25 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and different staple heights
US7669746B2 (en) 2005-08-31 2010-03-02 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US9237891B2 (en) 2005-08-31 2016-01-19 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US7934630B2 (en) 2005-08-31 2011-05-03 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US11246590B2 (en) 2005-08-31 2022-02-15 Cilag Gmbh International Staple cartridge including staple drivers having different unfired heights
US20070194079A1 (en) 2005-08-31 2007-08-23 Hueil Joseph C Surgical stapling device with staple drivers of different height
US11484312B2 (en) 2005-08-31 2022-11-01 Cilag Gmbh International Staple cartridge comprising a staple driver arrangement
US20070106317A1 (en) 2005-11-09 2007-05-10 Shelton Frederick E Iv Hydraulically and electrically actuated articulation joints for surgical instruments
US20110006101A1 (en) 2009-02-06 2011-01-13 EthiconEndo-Surgery, Inc. Motor driven surgical fastener device with cutting member lockout arrangements
US20110024477A1 (en) 2009-02-06 2011-02-03 Hall Steven G Driven Surgical Stapler Improvements
US11793518B2 (en) 2006-01-31 2023-10-24 Cilag Gmbh International Powered surgical instruments with firing system lockout arrangements
US7845537B2 (en) 2006-01-31 2010-12-07 Ethicon Endo-Surgery, Inc. Surgical instrument having recording capabilities
US9861359B2 (en) 2006-01-31 2018-01-09 Ethicon Llc Powered surgical instruments with firing system lockout arrangements
US8708213B2 (en) 2006-01-31 2014-04-29 Ethicon Endo-Surgery, Inc. Surgical instrument having a feedback system
US7753904B2 (en) 2006-01-31 2010-07-13 Ethicon Endo-Surgery, Inc. Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US20120292367A1 (en) 2006-01-31 2012-11-22 Ethicon Endo-Surgery, Inc. Robotically-controlled end effector
US11278279B2 (en) 2006-01-31 2022-03-22 Cilag Gmbh International Surgical instrument assembly
US8820603B2 (en) 2006-01-31 2014-09-02 Ethicon Endo-Surgery, Inc. Accessing data stored in a memory of a surgical instrument
US20110290856A1 (en) 2006-01-31 2011-12-01 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical instrument with force-feedback capabilities
US8186555B2 (en) 2006-01-31 2012-05-29 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting and fastening instrument with mechanical closure system
US11224427B2 (en) 2006-01-31 2022-01-18 Cilag Gmbh International Surgical stapling system including a console and retraction assembly
US20070225562A1 (en) 2006-03-23 2007-09-27 Ethicon Endo-Surgery, Inc. Articulating endoscopic accessory channel
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
CA2650819A1 (en) 2006-05-11 2007-11-22 Air Products And Chemicals, Inc. Personal care compositions containing functionalized polymers
US7862540B2 (en) * 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US20070268340A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Ophthalmic Injection System and Method Using Piezoelectric Array
US20070270744A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Limited Reuse Assembly For Ophthalmic Injection Device
US7887521B2 (en) * 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US20070270768A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Mechanical Linkage Mechanism For Ophthalmic Injection Device
US7811252B2 (en) * 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US7674243B2 (en) * 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US20070270750A1 (en) * 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US8322455B2 (en) 2006-06-27 2012-12-04 Ethicon Endo-Surgery, Inc. Manually driven surgical cutting and fastening instrument
US20080097379A1 (en) * 2006-09-26 2008-04-24 Alcon Manufacturing, Ltd. Ophthalmic injection method
US20080097390A1 (en) * 2006-09-27 2008-04-24 Alcon Manufacturing, Ltd. Spring actuated delivery system
US10568652B2 (en) 2006-09-29 2020-02-25 Ethicon Llc Surgical staples having attached drivers of different heights and stapling instruments for deploying the same
US7506791B2 (en) 2006-09-29 2009-03-24 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with mechanical mechanism for limiting maximum tissue compression
US10130359B2 (en) 2006-09-29 2018-11-20 Ethicon Llc Method for forming a staple
CN102014987A (en) * 2006-10-16 2011-04-13 爱尔康研究有限公司 Method of operating ophthalmic hand piece with disposable end
EP2063829B1 (en) * 2006-10-16 2010-12-08 Alcon Research, Ltd. Universal rechargeable limited reuse assembly for ophthalmic hand piece
US20080281292A1 (en) * 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
US9022970B2 (en) * 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
RU2461597C2 (en) 2006-11-02 2012-09-20 Эйвери Деннисон Корпорейшн Emulsion adhesive for washable film
US20090246155A1 (en) * 2006-12-05 2009-10-01 Landec Corporation Compositions and methods for personal care
US20090263346A1 (en) * 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
EP2101745A4 (en) * 2006-12-05 2009-12-30 Landec Corp Delivery of drugs
US8399007B2 (en) * 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US11291441B2 (en) 2007-01-10 2022-04-05 Cilag Gmbh International Surgical instrument with wireless communication between control unit and remote sensor
US8652120B2 (en) 2007-01-10 2014-02-18 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between control unit and sensor transponders
US8684253B2 (en) 2007-01-10 2014-04-01 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor
US8540128B2 (en) 2007-01-11 2013-09-24 Ethicon Endo-Surgery, Inc. Surgical stapling device with a curved end effector
US11039836B2 (en) 2007-01-11 2021-06-22 Cilag Gmbh International Staple cartridge for use with a surgical stapling instrument
US8727197B2 (en) 2007-03-15 2014-05-20 Ethicon Endo-Surgery, Inc. Staple cartridge cavity configuration with cooperative surgical staple
US8893946B2 (en) 2007-03-28 2014-11-25 Ethicon Endo-Surgery, Inc. Laparoscopic tissue thickness and clamp load measuring devices
US11857181B2 (en) 2007-06-04 2024-01-02 Cilag Gmbh International Robotically-controlled shaft based rotary drive systems for surgical instruments
US8931682B2 (en) 2007-06-04 2015-01-13 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US7753245B2 (en) 2007-06-22 2010-07-13 Ethicon Endo-Surgery, Inc. Surgical stapling instruments
US8308040B2 (en) 2007-06-22 2012-11-13 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulatable end effector
US11849941B2 (en) 2007-06-29 2023-12-26 Cilag Gmbh International Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis
US20090018548A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Intraocular Lens Injection Device with Removable Cartridge
US20090018512A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Ophthalmic Injector
US7740619B2 (en) * 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
US7629768B2 (en) * 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US20090036842A1 (en) * 2007-08-03 2009-02-05 Raffi Pinedjian Consumable Activation Lever For Injection Device
TWI498136B (en) * 2007-10-09 2015-09-01 Alcon Res Ltd An injection device for delivering a rate and temperature-dependent substance into the eye and method of preparing the same
TWI451862B (en) * 2007-10-09 2014-09-11 Alcon Res Ltd Thermal coefficient driven drug pellet size for ophthalmic injection
US8114883B2 (en) * 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
US8561870B2 (en) 2008-02-13 2013-10-22 Ethicon Endo-Surgery, Inc. Surgical stapling instrument
US9179912B2 (en) 2008-02-14 2015-11-10 Ethicon Endo-Surgery, Inc. Robotically-controlled motorized surgical cutting and fastening instrument
BRPI0901282A2 (en) 2008-02-14 2009-11-17 Ethicon Endo Surgery Inc surgical cutting and fixation instrument with rf electrodes
US8636736B2 (en) 2008-02-14 2014-01-28 Ethicon Endo-Surgery, Inc. Motorized surgical cutting and fastening instrument
US8573465B2 (en) 2008-02-14 2013-11-05 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical end effector system with rotary actuated closure systems
US8758391B2 (en) 2008-02-14 2014-06-24 Ethicon Endo-Surgery, Inc. Interchangeable tools for surgical instruments
US8657174B2 (en) 2008-02-14 2014-02-25 Ethicon Endo-Surgery, Inc. Motorized surgical cutting and fastening instrument having handle based power source
US7866527B2 (en) 2008-02-14 2011-01-11 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with interlockable firing system
US7819298B2 (en) 2008-02-14 2010-10-26 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with control features operable with one hand
US9770245B2 (en) 2008-02-15 2017-09-26 Ethicon Llc Layer arrangements for surgical staple cartridges
US11272927B2 (en) 2008-02-15 2022-03-15 Cilag Gmbh International Layer arrangements for surgical staple cartridges
PL3476312T3 (en) 2008-09-19 2024-03-11 Ethicon Llc Surgical stapler with apparatus for adjusting staple height
US7857186B2 (en) 2008-09-19 2010-12-28 Ethicon Endo-Surgery, Inc. Surgical stapler having an intermediate closing position
US8210411B2 (en) 2008-09-23 2012-07-03 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument
US11648005B2 (en) 2008-09-23 2023-05-16 Cilag Gmbh International Robotically-controlled motorized surgical instrument with an end effector
US9386983B2 (en) 2008-09-23 2016-07-12 Ethicon Endo-Surgery, Llc Robotically-controlled motorized surgical instrument
US9005230B2 (en) 2008-09-23 2015-04-14 Ethicon Endo-Surgery, Inc. Motorized surgical instrument
US8608045B2 (en) 2008-10-10 2013-12-17 Ethicon Endo-Sugery, Inc. Powered surgical cutting and stapling apparatus with manually retractable firing system
US9012477B2 (en) * 2009-01-06 2015-04-21 Nuvo Research Inc. Method of treating neuropathic pain
US8517239B2 (en) 2009-02-05 2013-08-27 Ethicon Endo-Surgery, Inc. Surgical stapling instrument comprising a magnetic element driver
US8444036B2 (en) 2009-02-06 2013-05-21 Ethicon Endo-Surgery, Inc. Motor driven surgical fastener device with mechanisms for adjusting a tissue gap within the end effector
CN102341048A (en) 2009-02-06 2012-02-01 伊西康内外科公司 Driven surgical stapler improvements
CN102449089A (en) 2009-03-30 2012-05-09 艾利丹尼森公司 Removable adhesive label containing inherently shrinkable polymeric film
RU2011143933A (en) 2009-03-30 2013-05-10 Авери Деннисон Корпорейшн REMOVABLE SELF-ADHESIVE LABEL, INCLUDING A LAYER OF A POLYMER FILM WITH A HIGH ELASTIC MODULE AT TENSION
PL2415042T3 (en) 2009-03-30 2017-08-31 Avery Dennison Corporation Removable adhesive label containing polymeric film layer having water affinity
EP2413837A4 (en) * 2009-04-01 2013-10-23 Jie Zhang Methods for treating myofascial, muscle, and/or back pain
AU2010246064A1 (en) * 2009-05-04 2011-12-22 Zars Pharma, Inc. Methods of treating pains associated with neuroma, nerve entrapment, and other conditions
US9186334B2 (en) 2009-05-04 2015-11-17 Nuvo Research Inc. Heat assisted lidocaine and tetracaine for transdermal analgesia
US8632511B2 (en) * 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
EP2437735A4 (en) * 2009-06-04 2013-04-03 Landec Corp Compositions and methods for delivery of materials
WO2010144755A2 (en) * 2009-06-11 2010-12-16 Landec Corporation Compositions and methods for delivery of materials
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
CA2770735C (en) 2009-08-13 2017-07-18 Acufocus, Inc. Masked intraocular implants and lenses
WO2015023961A1 (en) 2013-08-15 2015-02-19 International Flavors & Fragrances Inc. Polyurea or polyurethane capsules
CN102120167B (en) 2009-09-18 2014-10-29 国际香料和香精公司 encapsulated active material
US9233063B2 (en) * 2009-12-17 2016-01-12 Air Products And Chemicals, Inc. Polymeric compositions for personal care products
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8220688B2 (en) 2009-12-24 2012-07-17 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument with electric actuator directional control assembly
US8851354B2 (en) 2009-12-24 2014-10-07 Ethicon Endo-Surgery, Inc. Surgical cutting instrument that analyzes tissue thickness
CN102834096A (en) 2010-01-14 2012-12-19 卢福研究公司 Solid-forming local anesthetic formulations for pain control
US8783543B2 (en) 2010-07-30 2014-07-22 Ethicon Endo-Surgery, Inc. Tissue acquisition arrangements and methods for surgical stapling devices
US8671871B2 (en) 2010-09-29 2014-03-18 Temptime Corporation Temperature-activated time-temperature indicator
US9629814B2 (en) 2010-09-30 2017-04-25 Ethicon Endo-Surgery, Llc Tissue thickness compensator configured to redistribute compressive forces
US9204880B2 (en) 2012-03-28 2015-12-08 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising capsules defining a low pressure environment
US9055941B2 (en) 2011-09-23 2015-06-16 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck
US9282962B2 (en) 2010-09-30 2016-03-15 Ethicon Endo-Surgery, Llc Adhesive film laminate
US9016542B2 (en) 2010-09-30 2015-04-28 Ethicon Endo-Surgery, Inc. Staple cartridge comprising compressible distortion resistant components
US9314246B2 (en) 2010-09-30 2016-04-19 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorporating an anti-inflammatory agent
US9332974B2 (en) 2010-09-30 2016-05-10 Ethicon Endo-Surgery, Llc Layered tissue thickness compensator
US9517063B2 (en) * 2012-03-28 2016-12-13 Ethicon Endo-Surgery, Llc Movable member for use with a tissue thickness compensator
US9220501B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensators
US9386988B2 (en) 2010-09-30 2016-07-12 Ethicon End-Surgery, LLC Retainer assembly including a tissue thickness compensator
US9433419B2 (en) 2010-09-30 2016-09-06 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a plurality of layers
US11812965B2 (en) 2010-09-30 2023-11-14 Cilag Gmbh International Layer of material for a surgical end effector
US9364233B2 (en) 2010-09-30 2016-06-14 Ethicon Endo-Surgery, Llc Tissue thickness compensators for circular surgical staplers
US9414838B2 (en) * 2012-03-28 2016-08-16 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprised of a plurality of materials
US11849952B2 (en) 2010-09-30 2023-12-26 Cilag Gmbh International Staple cartridge comprising staples positioned within a compressible portion thereof
US9211120B2 (en) 2011-04-29 2015-12-15 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a plurality of medicaments
EP2621356B1 (en) 2010-09-30 2018-03-07 Ethicon LLC Fastener system comprising a retention matrix and an alignment matrix
US9307989B2 (en) 2012-03-28 2016-04-12 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorportating a hydrophobic agent
US11298125B2 (en) 2010-09-30 2022-04-12 Cilag Gmbh International Tissue stapler having a thickness compensator
US10945731B2 (en) 2010-09-30 2021-03-16 Ethicon Llc Tissue thickness compensator comprising controlled release and expansion
US8695866B2 (en) 2010-10-01 2014-04-15 Ethicon Endo-Surgery, Inc. Surgical instrument having a power control circuit
US9888530B2 (en) 2011-02-14 2018-02-06 Bernard Fryshman Induction cooking apparatus and induction cookware
CA2834649C (en) 2011-04-29 2021-02-16 Ethicon Endo-Surgery, Inc. Staple cartridge comprising staples positioned within a compressible portion thereof
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US11207064B2 (en) 2011-05-27 2021-12-28 Cilag Gmbh International Automated end effector component reloading system for use with a robotic system
US9050084B2 (en) 2011-09-23 2015-06-09 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck arrangement
CA2857306C (en) 2011-12-02 2017-07-25 Acufocus, Inc. Ocular mask having selective spectral transmission
US9044230B2 (en) 2012-02-13 2015-06-02 Ethicon Endo-Surgery, Inc. Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
CN104379068B (en) 2012-03-28 2017-09-22 伊西康内外科公司 Holding device assembly including tissue thickness compensation part
US20130256373A1 (en) * 2012-03-28 2013-10-03 Ethicon Endo-Surgery, Inc. Devices and methods for attaching tissue thickness compensating materials to surgical stapling instruments
BR112014024102B1 (en) 2012-03-28 2022-03-03 Ethicon Endo-Surgery, Inc CLAMP CARTRIDGE ASSEMBLY FOR A SURGICAL INSTRUMENT AND END ACTUATOR ASSEMBLY FOR A SURGICAL INSTRUMENT
BR112014024098B1 (en) 2012-03-28 2021-05-25 Ethicon Endo-Surgery, Inc. staple cartridge
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
JP6290201B2 (en) 2012-06-28 2018-03-07 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Lockout for empty clip cartridge
US9226751B2 (en) 2012-06-28 2016-01-05 Ethicon Endo-Surgery, Inc. Surgical instrument system including replaceable end effectors
US9289256B2 (en) 2012-06-28 2016-03-22 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
US11278284B2 (en) 2012-06-28 2022-03-22 Cilag Gmbh International Rotary drive arrangements for surgical instruments
US9204879B2 (en) 2012-06-28 2015-12-08 Ethicon Endo-Surgery, Inc. Flexible drive member
US20140001231A1 (en) 2012-06-28 2014-01-02 Ethicon Endo-Surgery, Inc. Firing system lockout arrangements for surgical instruments
US9282974B2 (en) 2012-06-28 2016-03-15 Ethicon Endo-Surgery, Llc Empty clip cartridge lockout
BR112014032776B1 (en) 2012-06-28 2021-09-08 Ethicon Endo-Surgery, Inc SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM
US9386984B2 (en) 2013-02-08 2016-07-12 Ethicon Endo-Surgery, Llc Staple cartridge comprising a releasable cover
US8985762B2 (en) 2013-02-27 2015-03-24 Beta Frames Llc Eyeglass frames
JP6345707B2 (en) 2013-03-01 2018-06-20 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Surgical instrument with soft stop
US20140246475A1 (en) 2013-03-01 2014-09-04 Ethicon Endo-Surgery, Inc. Control methods for surgical instruments with removable implement portions
JP6382235B2 (en) 2013-03-01 2018-08-29 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Articulatable surgical instrument with a conductive path for signal communication
US20140263552A1 (en) 2013-03-13 2014-09-18 Ethicon Endo-Surgery, Inc. Staple cartridge tissue thickness sensor system
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9332987B2 (en) 2013-03-14 2016-05-10 Ethicon Endo-Surgery, Llc Control arrangements for a drive member of a surgical instrument
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9332984B2 (en) 2013-03-27 2016-05-10 Ethicon Endo-Surgery, Llc Fastener cartridge assemblies
US9572577B2 (en) 2013-03-27 2017-02-21 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a tissue thickness compensator including openings therein
US9795384B2 (en) 2013-03-27 2017-10-24 Ethicon Llc Fastener cartridge comprising a tissue thickness compensator and a gap setting element
US9844368B2 (en) 2013-04-16 2017-12-19 Ethicon Llc Surgical system comprising first and second drive systems
BR112015026109B1 (en) 2013-04-16 2022-02-22 Ethicon Endo-Surgery, Inc surgical instrument
US9574644B2 (en) 2013-05-30 2017-02-21 Ethicon Endo-Surgery, Llc Power module for use with a surgical instrument
JP6416260B2 (en) 2013-08-23 2018-10-31 エシコン エルエルシー Firing member retractor for a powered surgical instrument
US20150053746A1 (en) 2013-08-23 2015-02-26 Ethicon Endo-Surgery, Inc. Torque optimization for surgical instruments
US9610228B2 (en) 2013-10-11 2017-04-04 International Flavors & Fragrances Inc. Terpolymer-coated polymer encapsulated active material
ES2790417T3 (en) 2013-10-18 2020-10-27 Int Flavors & Fragrances Inc Hybrid fragrance encapsulation formulation and method of using it
ES2658226T3 (en) 2013-10-18 2018-03-08 International Flavors & Fragrances Inc. Fluid and stable formulation of silica capsules
US9839428B2 (en) 2013-12-23 2017-12-12 Ethicon Llc Surgical cutting and stapling instruments with independent jaw control features
US9724092B2 (en) 2013-12-23 2017-08-08 Ethicon Llc Modular surgical instruments
US9968354B2 (en) 2013-12-23 2018-05-15 Ethicon Llc Surgical staples and methods for making the same
US20150173756A1 (en) 2013-12-23 2015-06-25 Ethicon Endo-Surgery, Inc. Surgical cutting and stapling methods
US9962161B2 (en) 2014-02-12 2018-05-08 Ethicon Llc Deliverable surgical instrument
US9839422B2 (en) 2014-02-24 2017-12-12 Ethicon Llc Implantable layers and methods for altering implantable layers for use with surgical fastening instruments
CN106232029B (en) 2014-02-24 2019-04-12 伊西康内外科有限责任公司 Fastening system including firing member locking piece
US10201364B2 (en) 2014-03-26 2019-02-12 Ethicon Llc Surgical instrument comprising a rotatable shaft
US9733663B2 (en) 2014-03-26 2017-08-15 Ethicon Llc Power management through segmented circuit and variable voltage protection
US10004497B2 (en) 2014-03-26 2018-06-26 Ethicon Llc Interface systems for use with surgical instruments
BR112016021943B1 (en) 2014-03-26 2022-06-14 Ethicon Endo-Surgery, Llc SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE
US9913642B2 (en) 2014-03-26 2018-03-13 Ethicon Llc Surgical instrument comprising a sensor system
US10561422B2 (en) 2014-04-16 2020-02-18 Ethicon Llc Fastener cartridge comprising deployable tissue engaging members
US10327764B2 (en) 2014-09-26 2019-06-25 Ethicon Llc Method for creating a flexible staple line
BR112016023825B1 (en) 2014-04-16 2022-08-02 Ethicon Endo-Surgery, Llc STAPLE CARTRIDGE FOR USE WITH A SURGICAL STAPLER AND STAPLE CARTRIDGE FOR USE WITH A SURGICAL INSTRUMENT
US20150297223A1 (en) 2014-04-16 2015-10-22 Ethicon Endo-Surgery, Inc. Fastener cartridges including extensions having different configurations
JP6636452B2 (en) 2014-04-16 2020-01-29 エシコン エルエルシーEthicon LLC Fastener cartridge including extension having different configurations
JP6532889B2 (en) 2014-04-16 2019-06-19 エシコン エルエルシーEthicon LLC Fastener cartridge assembly and staple holder cover arrangement
US10045781B2 (en) 2014-06-13 2018-08-14 Ethicon Llc Closure lockout systems for surgical instruments
BR112017004361B1 (en) 2014-09-05 2023-04-11 Ethicon Llc ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT
US11311294B2 (en) 2014-09-05 2022-04-26 Cilag Gmbh International Powered medical device including measurement of closure state of jaws
US10111679B2 (en) 2014-09-05 2018-10-30 Ethicon Llc Circuitry and sensors for powered medical device
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
US11523821B2 (en) 2014-09-26 2022-12-13 Cilag Gmbh International Method for creating a flexible staple line
JP6648119B2 (en) 2014-09-26 2020-02-14 エシコン エルエルシーEthicon LLC Surgical stapling buttress and accessory materials
US10076325B2 (en) 2014-10-13 2018-09-18 Ethicon Llc Surgical stapling apparatus comprising a tissue stop
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US11141153B2 (en) 2014-10-29 2021-10-12 Cilag Gmbh International Staple cartridges comprising driver arrangements
US10517594B2 (en) 2014-10-29 2019-12-31 Ethicon Llc Cartridge assemblies for surgical staplers
US9844376B2 (en) 2014-11-06 2017-12-19 Ethicon Llc Staple cartridge comprising a releasable adjunct material
US10736636B2 (en) 2014-12-10 2020-08-11 Ethicon Llc Articulatable surgical instrument system
MX2017008108A (en) 2014-12-18 2018-03-06 Ethicon Llc Surgical instrument with an anvil that is selectively movable about a discrete non-movable axis relative to a staple cartridge.
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US10188385B2 (en) 2014-12-18 2019-01-29 Ethicon Llc Surgical instrument system comprising lockable systems
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US10004501B2 (en) 2014-12-18 2018-06-26 Ethicon Llc Surgical instruments with improved closure arrangements
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US10117649B2 (en) 2014-12-18 2018-11-06 Ethicon Llc Surgical instrument assembly comprising a lockable articulation system
US10180463B2 (en) 2015-02-27 2019-01-15 Ethicon Llc Surgical apparatus configured to assess whether a performance parameter of the surgical apparatus is within an acceptable performance band
US9993258B2 (en) 2015-02-27 2018-06-12 Ethicon Llc Adaptable surgical instrument handle
US10321907B2 (en) 2015-02-27 2019-06-18 Ethicon Llc System for monitoring whether a surgical instrument needs to be serviced
US11154301B2 (en) 2015-02-27 2021-10-26 Cilag Gmbh International Modular stapling assembly
US9895148B2 (en) 2015-03-06 2018-02-20 Ethicon Endo-Surgery, Llc Monitoring speed control and precision incrementing of motor for powered surgical instruments
US9924961B2 (en) 2015-03-06 2018-03-27 Ethicon Endo-Surgery, Llc Interactive feedback system for powered surgical instruments
US9808246B2 (en) 2015-03-06 2017-11-07 Ethicon Endo-Surgery, Llc Method of operating a powered surgical instrument
US10687806B2 (en) 2015-03-06 2020-06-23 Ethicon Llc Adaptive tissue compression techniques to adjust closure rates for multiple tissue types
US10045776B2 (en) 2015-03-06 2018-08-14 Ethicon Llc Control techniques and sub-processor contained within modular shaft with select control processing from handle
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
JP2020121162A (en) 2015-03-06 2020-08-13 エシコン エルエルシーEthicon LLC Time dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
US10548504B2 (en) 2015-03-06 2020-02-04 Ethicon Llc Overlaid multi sensor radio frequency (RF) electrode system to measure tissue compression
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft
US10617412B2 (en) 2015-03-06 2020-04-14 Ethicon Llc System for detecting the mis-insertion of a staple cartridge into a surgical stapler
US10441279B2 (en) 2015-03-06 2019-10-15 Ethicon Llc Multiple level thresholds to modify operation of powered surgical instruments
US10213201B2 (en) 2015-03-31 2019-02-26 Ethicon Llc Stapling end effector configured to compensate for an uneven gap between a first jaw and a second jaw
US10368861B2 (en) 2015-06-18 2019-08-06 Ethicon Llc Dual articulation drive system arrangements for articulatable surgical instruments
US11058425B2 (en) 2015-08-17 2021-07-13 Ethicon Llc Implantable layers for a surgical instrument
JP6828018B2 (en) 2015-08-26 2021-02-10 エシコン エルエルシーEthicon LLC Surgical staple strips that allow you to change the characteristics of staples and facilitate filling into cartridges
US10357251B2 (en) 2015-08-26 2019-07-23 Ethicon Llc Surgical staples comprising hardness variations for improved fastening of tissue
WO2017040244A1 (en) 2015-08-28 2017-03-09 Landec Corporation Coated substrates and compositions for coating substrates
MX2022006192A (en) 2015-09-02 2022-06-16 Ethicon Llc Surgical staple configurations with camming surfaces located between portions supporting surgical staples.
US10238390B2 (en) 2015-09-02 2019-03-26 Ethicon Llc Surgical staple cartridges with driver arrangements for establishing herringbone staple patterns
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
US10327769B2 (en) 2015-09-23 2019-06-25 Ethicon Llc Surgical stapler having motor control based on a drive system component
US10105139B2 (en) 2015-09-23 2018-10-23 Ethicon Llc Surgical stapler having downstream current-based motor control
US10076326B2 (en) 2015-09-23 2018-09-18 Ethicon Llc Surgical stapler having current mirror-based motor control
US10238386B2 (en) 2015-09-23 2019-03-26 Ethicon Llc Surgical stapler having motor control based on an electrical parameter related to a motor current
US10363036B2 (en) 2015-09-23 2019-07-30 Ethicon Llc Surgical stapler having force-based motor control
US10085751B2 (en) 2015-09-23 2018-10-02 Ethicon Llc Surgical stapler having temperature-based motor control
US10299878B2 (en) 2015-09-25 2019-05-28 Ethicon Llc Implantable adjunct systems for determining adjunct skew
US11890015B2 (en) 2015-09-30 2024-02-06 Cilag Gmbh International Compressible adjunct with crossing spacer fibers
US10980539B2 (en) 2015-09-30 2021-04-20 Ethicon Llc Implantable adjunct comprising bonded layers
US10285699B2 (en) 2015-09-30 2019-05-14 Ethicon Llc Compressible adjunct
US10327777B2 (en) 2015-09-30 2019-06-25 Ethicon Llc Implantable layer comprising plastically deformed fibers
EP3359987B1 (en) 2015-10-05 2024-02-28 AcuFocus, Inc. Methods of molding intraocular lenses
CA3005891C (en) 2015-11-24 2023-12-12 Acufocus, Inc. Toric small aperture intraocular lens with extended depth of focus
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US20170224332A1 (en) 2016-02-09 2017-08-10 Ethicon Endo-Surgery, Llc Surgical instruments with non-symmetrical articulation arrangements
BR112018016098B1 (en) 2016-02-09 2023-02-23 Ethicon Llc SURGICAL INSTRUMENT
US10258331B2 (en) 2016-02-12 2019-04-16 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11064997B2 (en) 2016-04-01 2021-07-20 Cilag Gmbh International Surgical stapling instrument
US10617413B2 (en) 2016-04-01 2020-04-14 Ethicon Llc Closure system arrangements for surgical cutting and stapling devices with separate and distinct firing shafts
US10828028B2 (en) 2016-04-15 2020-11-10 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10405859B2 (en) 2016-04-15 2019-09-10 Ethicon Llc Surgical instrument with adjustable stop/start control during a firing motion
US10357247B2 (en) 2016-04-15 2019-07-23 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10335145B2 (en) 2016-04-15 2019-07-02 Ethicon Llc Modular surgical instrument with configurable operating mode
US10426467B2 (en) 2016-04-15 2019-10-01 Ethicon Llc Surgical instrument with detection sensors
US11179150B2 (en) 2016-04-15 2021-11-23 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US11607239B2 (en) 2016-04-15 2023-03-21 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10456137B2 (en) 2016-04-15 2019-10-29 Ethicon Llc Staple formation detection mechanisms
US10492783B2 (en) 2016-04-15 2019-12-03 Ethicon, Llc Surgical instrument with improved stop/start control during a firing motion
US11317917B2 (en) 2016-04-18 2022-05-03 Cilag Gmbh International Surgical stapling system comprising a lockable firing assembly
US10368867B2 (en) 2016-04-18 2019-08-06 Ethicon Llc Surgical instrument comprising a lockout
US20170296173A1 (en) 2016-04-18 2017-10-19 Ethicon Endo-Surgery, Llc Method for operating a surgical instrument
US10105069B2 (en) 2016-04-20 2018-10-23 Bernard Fryshman Induction heating applications
USD850617S1 (en) 2016-06-24 2019-06-04 Ethicon Llc Surgical fastener cartridge
USD826405S1 (en) 2016-06-24 2018-08-21 Ethicon Llc Surgical fastener
USD847989S1 (en) 2016-06-24 2019-05-07 Ethicon Llc Surgical fastener cartridge
JP6957532B2 (en) 2016-06-24 2021-11-02 エシコン エルエルシーEthicon LLC Staple cartridges including wire staples and punched staples
US10702270B2 (en) 2016-06-24 2020-07-07 Ethicon Llc Stapling system for use with wire staples and stamped staples
MX2019003078A (en) 2016-09-16 2019-07-08 Int Flavors & Fragrances Inc Microcapsule compositions stabilized with viscosity control agents.
US10687810B2 (en) 2016-12-21 2020-06-23 Ethicon Llc Stepped staple cartridge with tissue retention and gap setting features
US10993715B2 (en) 2016-12-21 2021-05-04 Ethicon Llc Staple cartridge comprising staples with different clamping breadths
US10426471B2 (en) 2016-12-21 2019-10-01 Ethicon Llc Surgical instrument with multiple failure response modes
US11090048B2 (en) 2016-12-21 2021-08-17 Cilag Gmbh International Method for resetting a fuse of a surgical instrument shaft
US10588631B2 (en) 2016-12-21 2020-03-17 Ethicon Llc Surgical instruments with positive jaw opening features
US10856868B2 (en) 2016-12-21 2020-12-08 Ethicon Llc Firing member pin configurations
US10959727B2 (en) 2016-12-21 2021-03-30 Ethicon Llc Articulatable surgical end effector with asymmetric shaft arrangement
US10973516B2 (en) 2016-12-21 2021-04-13 Ethicon Llc Surgical end effectors and adaptable firing members therefor
US10945727B2 (en) 2016-12-21 2021-03-16 Ethicon Llc Staple cartridge with deformable driver retention features
JP7010956B2 (en) 2016-12-21 2022-01-26 エシコン エルエルシー How to staple tissue
US20180168648A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Durability features for end effectors and firing assemblies of surgical stapling instruments
US11419606B2 (en) 2016-12-21 2022-08-23 Cilag Gmbh International Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
MX2019007311A (en) 2016-12-21 2019-11-18 Ethicon Llc Surgical stapling systems.
US11684367B2 (en) 2016-12-21 2023-06-27 Cilag Gmbh International Stepped assembly having and end-of-life indicator
US20180168615A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
US10695055B2 (en) 2016-12-21 2020-06-30 Ethicon Llc Firing assembly comprising a lockout
US10918385B2 (en) 2016-12-21 2021-02-16 Ethicon Llc Surgical system comprising a firing member rotatable into an articulation state to articulate an end effector of the surgical system
US10888322B2 (en) 2016-12-21 2021-01-12 Ethicon Llc Surgical instrument comprising a cutting member
US20180168633A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Surgical stapling instruments and staple-forming anvils
US20180168625A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Surgical stapling instruments with smart staple cartridges
US11134942B2 (en) 2016-12-21 2021-10-05 Cilag Gmbh International Surgical stapling instruments and staple-forming anvils
US10568624B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Surgical instruments with jaws that are pivotable about a fixed axis and include separate and distinct closure and firing systems
US10682138B2 (en) 2016-12-21 2020-06-16 Ethicon Llc Bilaterally asymmetric staple forming pocket pairs
CN110099619B (en) 2016-12-21 2022-07-15 爱惜康有限责任公司 Lockout device for surgical end effector and replaceable tool assembly
US10328249B2 (en) * 2017-05-02 2019-06-25 Bernard Fryshman Applications using induction
US10980537B2 (en) 2017-06-20 2021-04-20 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations
US11090046B2 (en) 2017-06-20 2021-08-17 Cilag Gmbh International Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument
US11071554B2 (en) 2017-06-20 2021-07-27 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements
US11517325B2 (en) 2017-06-20 2022-12-06 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
US10888321B2 (en) 2017-06-20 2021-01-12 Ethicon Llc Systems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument
US10779820B2 (en) 2017-06-20 2020-09-22 Ethicon Llc Systems and methods for controlling motor speed according to user input for a surgical instrument
USD890784S1 (en) 2017-06-20 2020-07-21 Ethicon Llc Display panel with changeable graphical user interface
USD879809S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with changeable graphical user interface
US10881399B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument
US10368864B2 (en) 2017-06-20 2019-08-06 Ethicon Llc Systems and methods for controlling displaying motor velocity for a surgical instrument
US10327767B2 (en) 2017-06-20 2019-06-25 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10813639B2 (en) 2017-06-20 2020-10-27 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on system conditions
US10307170B2 (en) 2017-06-20 2019-06-04 Ethicon Llc Method for closed loop control of motor velocity of a surgical stapling and cutting instrument
US10646220B2 (en) 2017-06-20 2020-05-12 Ethicon Llc Systems and methods for controlling displacement member velocity for a surgical instrument
US11653914B2 (en) 2017-06-20 2023-05-23 Cilag Gmbh International Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector
US10390841B2 (en) 2017-06-20 2019-08-27 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10881396B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Surgical instrument with variable duration trigger arrangement
US11382638B2 (en) 2017-06-20 2022-07-12 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance
US10624633B2 (en) 2017-06-20 2020-04-21 Ethicon Llc Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument
USD879808S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with graphical user interface
US11266405B2 (en) 2017-06-27 2022-03-08 Cilag Gmbh International Surgical anvil manufacturing methods
US10993716B2 (en) 2017-06-27 2021-05-04 Ethicon Llc Surgical anvil arrangements
US11324503B2 (en) 2017-06-27 2022-05-10 Cilag Gmbh International Surgical firing member arrangements
US20180368844A1 (en) 2017-06-27 2018-12-27 Ethicon Llc Staple forming pocket arrangements
US10772629B2 (en) 2017-06-27 2020-09-15 Ethicon Llc Surgical anvil arrangements
US10856869B2 (en) 2017-06-27 2020-12-08 Ethicon Llc Surgical anvil arrangements
USD869655S1 (en) 2017-06-28 2019-12-10 Ethicon Llc Surgical fastener cartridge
US10765427B2 (en) 2017-06-28 2020-09-08 Ethicon Llc Method for articulating a surgical instrument
USD854151S1 (en) 2017-06-28 2019-07-16 Ethicon Llc Surgical instrument shaft
US11246592B2 (en) 2017-06-28 2022-02-15 Cilag Gmbh International Surgical instrument comprising an articulation system lockable to a frame
USD906355S1 (en) 2017-06-28 2020-12-29 Ethicon Llc Display screen or portion thereof with a graphical user interface for a surgical instrument
US10211586B2 (en) 2017-06-28 2019-02-19 Ethicon Llc Surgical shaft assemblies with watertight housings
US11564686B2 (en) 2017-06-28 2023-01-31 Cilag Gmbh International Surgical shaft assemblies with flexible interfaces
US10903685B2 (en) 2017-06-28 2021-01-26 Ethicon Llc Surgical shaft assemblies with slip ring assemblies forming capacitive channels
US10716614B2 (en) 2017-06-28 2020-07-21 Ethicon Llc Surgical shaft assemblies with slip ring assemblies with increased contact pressure
EP3420947B1 (en) 2017-06-28 2022-05-25 Cilag GmbH International Surgical instrument comprising selectively actuatable rotatable couplers
US11259805B2 (en) 2017-06-28 2022-03-01 Cilag Gmbh International Surgical instrument comprising firing member supports
USD851762S1 (en) 2017-06-28 2019-06-18 Ethicon Llc Anvil
US11484310B2 (en) 2017-06-28 2022-11-01 Cilag Gmbh International Surgical instrument comprising a shaft including a closure tube profile
US11478242B2 (en) 2017-06-28 2022-10-25 Cilag Gmbh International Jaw retainer arrangement for retaining a pivotable surgical instrument jaw in pivotable retaining engagement with a second surgical instrument jaw
US10898183B2 (en) 2017-06-29 2021-01-26 Ethicon Llc Robotic surgical instrument with closed loop feedback techniques for advancement of closure member during firing
US11007022B2 (en) 2017-06-29 2021-05-18 Ethicon Llc Closed loop velocity control techniques based on sensed tissue parameters for robotic surgical instrument
US10398434B2 (en) 2017-06-29 2019-09-03 Ethicon Llc Closed loop velocity control of closure member for robotic surgical instrument
US10932772B2 (en) 2017-06-29 2021-03-02 Ethicon Llc Methods for closed loop velocity control for robotic surgical instrument
US10258418B2 (en) 2017-06-29 2019-04-16 Ethicon Llc System for controlling articulation forces
US11471155B2 (en) 2017-08-03 2022-10-18 Cilag Gmbh International Surgical system bailout
US11304695B2 (en) 2017-08-03 2022-04-19 Cilag Gmbh International Surgical system shaft interconnection
US11944300B2 (en) 2017-08-03 2024-04-02 Cilag Gmbh International Method for operating a surgical system bailout
US10796471B2 (en) 2017-09-29 2020-10-06 Ethicon Llc Systems and methods of displaying a knife position for a surgical instrument
USD907647S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US10765429B2 (en) 2017-09-29 2020-09-08 Ethicon Llc Systems and methods for providing alerts according to the operational state of a surgical instrument
US10729501B2 (en) 2017-09-29 2020-08-04 Ethicon Llc Systems and methods for language selection of a surgical instrument
USD907648S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US10743872B2 (en) 2017-09-29 2020-08-18 Ethicon Llc System and methods for controlling a display of a surgical instrument
US11399829B2 (en) 2017-09-29 2022-08-02 Cilag Gmbh International Systems and methods of initiating a power shutdown mode for a surgical instrument
USD917500S1 (en) 2017-09-29 2021-04-27 Ethicon Llc Display screen or portion thereof with graphical user interface
US11134944B2 (en) 2017-10-30 2021-10-05 Cilag Gmbh International Surgical stapler knife motion controls
US11090075B2 (en) 2017-10-30 2021-08-17 Cilag Gmbh International Articulation features for surgical end effector
US10779903B2 (en) 2017-10-31 2020-09-22 Ethicon Llc Positive shaft rotation lock activated by jaw closure
US10842490B2 (en) 2017-10-31 2020-11-24 Ethicon Llc Cartridge body design with force reduction based on firing completion
US10743875B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Surgical end effectors with jaw stiffener arrangements configured to permit monitoring of firing member
US11197670B2 (en) 2017-12-15 2021-12-14 Cilag Gmbh International Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed
US10779826B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Methods of operating surgical end effectors
US11033267B2 (en) 2017-12-15 2021-06-15 Ethicon Llc Systems and methods of controlling a clamping member firing rate of a surgical instrument
US10743874B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Sealed adapters for use with electromechanical surgical instruments
US10687813B2 (en) 2017-12-15 2020-06-23 Ethicon Llc Adapters with firing stroke sensing arrangements for use in connection with electromechanical surgical instruments
US10869666B2 (en) 2017-12-15 2020-12-22 Ethicon Llc Adapters with control systems for controlling multiple motors of an electromechanical surgical instrument
US11006955B2 (en) 2017-12-15 2021-05-18 Ethicon Llc End effectors with positive jaw opening features for use with adapters for electromechanical surgical instruments
US10966718B2 (en) 2017-12-15 2021-04-06 Ethicon Llc Dynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments
US10828033B2 (en) 2017-12-15 2020-11-10 Ethicon Llc Handheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto
US10779825B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Adapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments
US11071543B2 (en) 2017-12-15 2021-07-27 Cilag Gmbh International Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges
US10835330B2 (en) 2017-12-19 2020-11-17 Ethicon Llc Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly
USD910847S1 (en) 2017-12-19 2021-02-16 Ethicon Llc Surgical instrument assembly
US10729509B2 (en) 2017-12-19 2020-08-04 Ethicon Llc Surgical instrument comprising closure and firing locking mechanism
US11020112B2 (en) 2017-12-19 2021-06-01 Ethicon Llc Surgical tools configured for interchangeable use with different controller interfaces
US10716565B2 (en) 2017-12-19 2020-07-21 Ethicon Llc Surgical instruments with dual articulation drivers
US11045270B2 (en) 2017-12-19 2021-06-29 Cilag Gmbh International Robotic attachment comprising exterior drive actuator
US11179152B2 (en) 2017-12-21 2021-11-23 Cilag Gmbh International Surgical instrument comprising a tissue grasping system
US11076853B2 (en) 2017-12-21 2021-08-03 Cilag Gmbh International Systems and methods of displaying a knife position during transection for a surgical instrument
US11129680B2 (en) 2017-12-21 2021-09-28 Cilag Gmbh International Surgical instrument comprising a projector
US11311290B2 (en) 2017-12-21 2022-04-26 Cilag Gmbh International Surgical instrument comprising an end effector dampener
US10946682B2 (en) * 2018-03-19 2021-03-16 Xerox Corporation Color changing expiration indicator
WO2019217471A1 (en) 2018-05-09 2019-11-14 Acufocus, Inc. Intraocular implant with removable optic
US10912559B2 (en) 2018-08-20 2021-02-09 Ethicon Llc Reinforced deformable anvil tip for surgical stapler anvil
US11045192B2 (en) 2018-08-20 2021-06-29 Cilag Gmbh International Fabricating techniques for surgical stapler anvils
US11253256B2 (en) 2018-08-20 2022-02-22 Cilag Gmbh International Articulatable motor powered surgical instruments with dedicated articulation motor arrangements
US11207065B2 (en) 2018-08-20 2021-12-28 Cilag Gmbh International Method for fabricating surgical stapler anvils
US11324501B2 (en) 2018-08-20 2022-05-10 Cilag Gmbh International Surgical stapling devices with improved closure members
USD914878S1 (en) 2018-08-20 2021-03-30 Ethicon Llc Surgical instrument anvil
US10779821B2 (en) 2018-08-20 2020-09-22 Ethicon Llc Surgical stapler anvils with tissue stop features configured to avoid tissue pinch
US11083458B2 (en) 2018-08-20 2021-08-10 Cilag Gmbh International Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions
US10842492B2 (en) 2018-08-20 2020-11-24 Ethicon Llc Powered articulatable surgical instruments with clutching and locking arrangements for linking an articulation drive system to a firing drive system
US10856870B2 (en) 2018-08-20 2020-12-08 Ethicon Llc Switching arrangements for motor powered articulatable surgical instruments
US11291440B2 (en) 2018-08-20 2022-04-05 Cilag Gmbh International Method for operating a powered articulatable surgical instrument
US11039834B2 (en) 2018-08-20 2021-06-22 Cilag Gmbh International Surgical stapler anvils with staple directing protrusions and tissue stability features
US11696761B2 (en) 2019-03-25 2023-07-11 Cilag Gmbh International Firing drive arrangements for surgical systems
US11147551B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11172929B2 (en) 2019-03-25 2021-11-16 Cilag Gmbh International Articulation drive arrangements for surgical systems
US11147553B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11432816B2 (en) 2019-04-30 2022-09-06 Cilag Gmbh International Articulation pin for a surgical instrument
US11903581B2 (en) 2019-04-30 2024-02-20 Cilag Gmbh International Methods for stapling tissue using a surgical instrument
US11426251B2 (en) 2019-04-30 2022-08-30 Cilag Gmbh International Articulation directional lights on a surgical instrument
US11253254B2 (en) 2019-04-30 2022-02-22 Cilag Gmbh International Shaft rotation actuator on a surgical instrument
US11471157B2 (en) 2019-04-30 2022-10-18 Cilag Gmbh International Articulation control mapping for a surgical instrument
US11648009B2 (en) 2019-04-30 2023-05-16 Cilag Gmbh International Rotatable jaw tip for a surgical instrument
US11452528B2 (en) 2019-04-30 2022-09-27 Cilag Gmbh International Articulation actuators for a surgical instrument
US11553971B2 (en) 2019-06-28 2023-01-17 Cilag Gmbh International Surgical RFID assemblies for display and communication
US11246678B2 (en) 2019-06-28 2022-02-15 Cilag Gmbh International Surgical stapling system having a frangible RFID tag
US11350938B2 (en) 2019-06-28 2022-06-07 Cilag Gmbh International Surgical instrument comprising an aligned rfid sensor
US11497492B2 (en) 2019-06-28 2022-11-15 Cilag Gmbh International Surgical instrument including an articulation lock
US11291451B2 (en) 2019-06-28 2022-04-05 Cilag Gmbh International Surgical instrument with battery compatibility verification functionality
US11523822B2 (en) 2019-06-28 2022-12-13 Cilag Gmbh International Battery pack including a circuit interrupter
US11298132B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Inlernational Staple cartridge including a honeycomb extension
US11298127B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Interational Surgical stapling system having a lockout mechanism for an incompatible cartridge
US11464601B2 (en) 2019-06-28 2022-10-11 Cilag Gmbh International Surgical instrument comprising an RFID system for tracking a movable component
US11638587B2 (en) 2019-06-28 2023-05-02 Cilag Gmbh International RFID identification systems for surgical instruments
US11684434B2 (en) 2019-06-28 2023-06-27 Cilag Gmbh International Surgical RFID assemblies for instrument operational setting control
US11771419B2 (en) 2019-06-28 2023-10-03 Cilag Gmbh International Packaging for a replaceable component of a surgical stapling system
US11219455B2 (en) 2019-06-28 2022-01-11 Cilag Gmbh International Surgical instrument including a lockout key
US11627959B2 (en) 2019-06-28 2023-04-18 Cilag Gmbh International Surgical instruments including manual and powered system lockouts
US11660163B2 (en) 2019-06-28 2023-05-30 Cilag Gmbh International Surgical system with RFID tags for updating motor assembly parameters
US11478241B2 (en) 2019-06-28 2022-10-25 Cilag Gmbh International Staple cartridge including projections
US11399837B2 (en) 2019-06-28 2022-08-02 Cilag Gmbh International Mechanisms for motor control adjustments of a motorized surgical instrument
US11259803B2 (en) 2019-06-28 2022-03-01 Cilag Gmbh International Surgical stapling system having an information encryption protocol
US11426167B2 (en) 2019-06-28 2022-08-30 Cilag Gmbh International Mechanisms for proper anvil attachment surgical stapling head assembly
US11224497B2 (en) 2019-06-28 2022-01-18 Cilag Gmbh International Surgical systems with multiple RFID tags
US11376098B2 (en) 2019-06-28 2022-07-05 Cilag Gmbh International Surgical instrument system comprising an RFID system
US11051807B2 (en) 2019-06-28 2021-07-06 Cilag Gmbh International Packaging assembly including a particulate trap
US11844520B2 (en) 2019-12-19 2023-12-19 Cilag Gmbh International Staple cartridge comprising driver retention members
US11464512B2 (en) 2019-12-19 2022-10-11 Cilag Gmbh International Staple cartridge comprising a curved deck surface
US11931033B2 (en) 2019-12-19 2024-03-19 Cilag Gmbh International Staple cartridge comprising a latch lockout
US11911032B2 (en) 2019-12-19 2024-02-27 Cilag Gmbh International Staple cartridge comprising a seating cam
US11446029B2 (en) 2019-12-19 2022-09-20 Cilag Gmbh International Staple cartridge comprising projections extending from a curved deck surface
US11529137B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Staple cartridge comprising driver retention members
US11529139B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Motor driven surgical instrument
US11234698B2 (en) 2019-12-19 2022-02-01 Cilag Gmbh International Stapling system comprising a clamp lockout and a firing lockout
US11576672B2 (en) 2019-12-19 2023-02-14 Cilag Gmbh International Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw
US11291447B2 (en) 2019-12-19 2022-04-05 Cilag Gmbh International Stapling instrument comprising independent jaw closing and staple firing systems
US11559304B2 (en) 2019-12-19 2023-01-24 Cilag Gmbh International Surgical instrument comprising a rapid closure mechanism
US11607219B2 (en) 2019-12-19 2023-03-21 Cilag Gmbh International Staple cartridge comprising a detachable tissue cutting knife
US11701111B2 (en) 2019-12-19 2023-07-18 Cilag Gmbh International Method for operating a surgical stapling instrument
US11504122B2 (en) 2019-12-19 2022-11-22 Cilag Gmbh International Surgical instrument comprising a nested firing member
US11304696B2 (en) 2019-12-19 2022-04-19 Cilag Gmbh International Surgical instrument comprising a powered articulation system
USD967421S1 (en) 2020-06-02 2022-10-18 Cilag Gmbh International Staple cartridge
USD966512S1 (en) 2020-06-02 2022-10-11 Cilag Gmbh International Staple cartridge
USD974560S1 (en) 2020-06-02 2023-01-03 Cilag Gmbh International Staple cartridge
USD975851S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD975278S1 (en) 2020-06-02 2023-01-10 Cilag Gmbh International Staple cartridge
USD976401S1 (en) 2020-06-02 2023-01-24 Cilag Gmbh International Staple cartridge
USD975850S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
US20220031320A1 (en) 2020-07-28 2022-02-03 Cilag Gmbh International Surgical instruments with flexible firing member actuator constraint arrangements
US11951761B2 (en) 2020-09-17 2024-04-09 Temptime Corporation Environmental history monitor with security features
US11241902B1 (en) 2020-09-17 2022-02-08 Temptime Corporation Environmental history monitor with positional displacement and security features
US11844518B2 (en) 2020-10-29 2023-12-19 Cilag Gmbh International Method for operating a surgical instrument
USD980425S1 (en) 2020-10-29 2023-03-07 Cilag Gmbh International Surgical instrument assembly
US11896217B2 (en) 2020-10-29 2024-02-13 Cilag Gmbh International Surgical instrument comprising an articulation lock
US11931025B2 (en) 2020-10-29 2024-03-19 Cilag Gmbh International Surgical instrument comprising a releasable closure drive lock
US11452526B2 (en) 2020-10-29 2022-09-27 Cilag Gmbh International Surgical instrument comprising a staged voltage regulation start-up system
US11779330B2 (en) 2020-10-29 2023-10-10 Cilag Gmbh International Surgical instrument comprising a jaw alignment system
US11534259B2 (en) 2020-10-29 2022-12-27 Cilag Gmbh International Surgical instrument comprising an articulation indicator
US11617577B2 (en) 2020-10-29 2023-04-04 Cilag Gmbh International Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly
US11517390B2 (en) 2020-10-29 2022-12-06 Cilag Gmbh International Surgical instrument comprising a limited travel switch
US11717289B2 (en) 2020-10-29 2023-08-08 Cilag Gmbh International Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable
US11890010B2 (en) 2020-12-02 2024-02-06 Cllag GmbH International Dual-sided reinforced reload for surgical instruments
US11653915B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Surgical instruments with sled location detection and adjustment features
US11944296B2 (en) 2020-12-02 2024-04-02 Cilag Gmbh International Powered surgical instruments with external connectors
US11653920B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Powered surgical instruments with communication interfaces through sterile barrier
US11849943B2 (en) 2020-12-02 2023-12-26 Cilag Gmbh International Surgical instrument with cartridge release mechanisms
US11737751B2 (en) 2020-12-02 2023-08-29 Cilag Gmbh International Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings
US11627960B2 (en) 2020-12-02 2023-04-18 Cilag Gmbh International Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections
US11744581B2 (en) 2020-12-02 2023-09-05 Cilag Gmbh International Powered surgical instruments with multi-phase tissue treatment
US11678882B2 (en) 2020-12-02 2023-06-20 Cilag Gmbh International Surgical instruments with interactive features to remedy incidental sled movements
US11812964B2 (en) 2021-02-26 2023-11-14 Cilag Gmbh International Staple cartridge comprising a power management circuit
US11701113B2 (en) 2021-02-26 2023-07-18 Cilag Gmbh International Stapling instrument comprising a separate power antenna and a data transfer antenna
US11749877B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Stapling instrument comprising a signal antenna
US11925349B2 (en) 2021-02-26 2024-03-12 Cilag Gmbh International Adjustment to transfer parameters to improve available power
US11793514B2 (en) 2021-02-26 2023-10-24 Cilag Gmbh International Staple cartridge comprising sensor array which may be embedded in cartridge body
US11730473B2 (en) 2021-02-26 2023-08-22 Cilag Gmbh International Monitoring of manufacturing life-cycle
US11751869B2 (en) 2021-02-26 2023-09-12 Cilag Gmbh International Monitoring of multiple sensors over time to detect moving characteristics of tissue
US11950779B2 (en) 2021-02-26 2024-04-09 Cilag Gmbh International Method of powering and communicating with a staple cartridge
US11696757B2 (en) 2021-02-26 2023-07-11 Cilag Gmbh International Monitoring of internal systems to detect and track cartridge motion status
US11723657B2 (en) 2021-02-26 2023-08-15 Cilag Gmbh International Adjustable communication based on available bandwidth and power capacity
US11950777B2 (en) 2021-02-26 2024-04-09 Cilag Gmbh International Staple cartridge comprising an information access control system
US11744583B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Distal communication array to tune frequency of RF systems
US11723658B2 (en) 2021-03-22 2023-08-15 Cilag Gmbh International Staple cartridge comprising a firing lockout
US11737749B2 (en) 2021-03-22 2023-08-29 Cilag Gmbh International Surgical stapling instrument comprising a retraction system
US11806011B2 (en) 2021-03-22 2023-11-07 Cilag Gmbh International Stapling instrument comprising tissue compression systems
US11826042B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Surgical instrument comprising a firing drive including a selectable leverage mechanism
US11826012B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Stapling instrument comprising a pulsed motor-driven firing rack
US11759202B2 (en) 2021-03-22 2023-09-19 Cilag Gmbh International Staple cartridge comprising an implantable layer
US11717291B2 (en) 2021-03-22 2023-08-08 Cilag Gmbh International Staple cartridge comprising staples configured to apply different tissue compression
US11896219B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Mating features between drivers and underside of a cartridge deck
US11849945B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Rotary-driven surgical stapling assembly comprising eccentrically driven firing member
US11903582B2 (en) 2021-03-24 2024-02-20 Cilag Gmbh International Leveraging surfaces for cartridge installation
US11857183B2 (en) 2021-03-24 2024-01-02 Cilag Gmbh International Stapling assembly components having metal substrates and plastic bodies
US11744603B2 (en) 2021-03-24 2023-09-05 Cilag Gmbh International Multi-axis pivot joints for surgical instruments and methods for manufacturing same
US11793516B2 (en) 2021-03-24 2023-10-24 Cilag Gmbh International Surgical staple cartridge comprising longitudinal support beam
US11832816B2 (en) 2021-03-24 2023-12-05 Cilag Gmbh International Surgical stapling assembly comprising nonplanar staples and planar staples
US11786243B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Firing members having flexible portions for adapting to a load during a surgical firing stroke
US11896218B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Method of using a powered stapling device
US11849944B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Drivers for fastener cartridge assemblies having rotary drive screws
US11786239B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Surgical instrument articulation joint arrangements comprising multiple moving linkage features
US11944336B2 (en) 2021-03-24 2024-04-02 Cilag Gmbh International Joint arrangements for multi-planar alignment and support of operational drive shafts in articulatable surgical instruments
US11826047B2 (en) 2021-05-28 2023-11-28 Cilag Gmbh International Stapling instrument comprising jaw mounts
US11877745B2 (en) 2021-10-18 2024-01-23 Cilag Gmbh International Surgical stapling assembly having longitudinally-repeating staple leg clusters
US11937816B2 (en) 2021-10-28 2024-03-26 Cilag Gmbh International Electrical lead arrangements for surgical instruments

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
CH337989A (en) * 1957-04-09 1959-04-30 Perrenoud Jean Pierre Dr Capsule
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
US3428729A (en) * 1966-12-20 1969-02-18 William R Anderson Controlled release formulation
US3485235A (en) * 1967-12-04 1969-12-23 Ronald Felson Capsule for the study and treatment of the digestive tract
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US3608549A (en) * 1970-01-15 1971-09-28 Merrill Edward Wilson Method of administering drugs and capsule therefor
US3737521A (en) * 1970-12-09 1973-06-05 Goodrich Co B F Formulation for sustained release of a biological agent
SE418749B (en) * 1977-04-04 1981-06-22 Ewos Ab FILM TRANSMISSION POLICIES FOR FEED LIFE AND MEDICINAL PRODUCTS AND PH-DEPENDENT SOLUBILITY CHARACTERISTICS IN Aqueous media AND PROCEDURE FOR THEIR PREPARATION
DE2908794C2 (en) * 1978-03-09 1984-09-13 Japan Atomic Energy Research Institute, Tokio/Tokyo Process for the production of a polymer preparation containing a physiologically active substance
EP0007731A3 (en) * 1978-07-28 1980-02-20 Imperial Chemical Industries Plc Process for the production of dispersions of hydrophobic particulate solids (e.g. pesticides) and the particulate dispersions thus obtained
FR2485370A1 (en) * 1980-06-30 1981-12-31 Commissariat Energie Atomique INERTE SUPPORT IN RETICULATED COPOLYMER, METHOD FOR PREPARING THE SAME AND USE THEREOF FOR PRODUCING DELAYED MEDICAMENTS
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US4687676A (en) * 1982-07-12 1987-08-18 Eastman Kodak Company Rumen-stable pellets
US4585452A (en) * 1983-04-12 1986-04-29 Key Pharmaceuticals, Inc. Transdermal systemic dosage forms
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches

Also Published As

Publication number Publication date
DE3873275D1 (en) 1992-09-03
ZA888421B (en) 1989-08-30
PH24852A (en) 1990-12-26
AR244087A1 (en) 1993-10-29
NZ226921A (en) 1990-11-27
DE3873275T2 (en) 1992-12-03
JPH0618788B2 (en) 1994-03-16
WO1989004648A1 (en) 1989-06-01
US4830855A (en) 1989-05-16
ATE78703T1 (en) 1992-08-15
KR0131598B1 (en) 1998-04-13
EP0317180A1 (en) 1989-05-24
IL88315A0 (en) 1989-06-30
ES2034260T3 (en) 1993-04-01
IL88315A (en) 1994-08-26
KR890701076A (en) 1989-12-19
JPH03502195A (en) 1991-05-23

Similar Documents

Publication Publication Date Title
EP0317180B1 (en) Temperature-controlled active agent dispenser
Roseman et al. Monolithic polymer devices
US5322695A (en) Moisture-vapor-permeable dressing
JP2649002B2 (en) Sustained-release drug distribution device using synergic polymer
US5173302A (en) Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
EP0184910B1 (en) Device for controlled release drug delivery
US5310559A (en) Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US5762952A (en) Transdermal delivery of active drugs
FI93223C (en) Limkompositoner
US5985304A (en) Barrier preventing wood pest access to wooden structures
EP0516026A1 (en) Hydrogel and method of producing same
CA1309948C (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
AU604693B2 (en) A laminar structure for administering a chemical at a controlled release rate
AU627163B2 (en) Temperature-controlled active agent dispenser
EP0523537B1 (en) Transdermal therapeutic system for the administration of drugs having bronchodilating activity
EP0274863B1 (en) Moisture-vapor-permeable dressing
JPS6117266B2 (en)
JPH0347243B2 (en)
JPS6239130B2 (en)
JP3167057B2 (en) Temperature-responsive hydrogel
JPS5811134A (en) Manufacture of polymer laminated sheet
JPH05163110A (en) Sustained release pheromone formulation
CA2060113A1 (en) Temperature activated controlled release device
Mhando et al. Two-stage release of benzocaine from sunflower oil/gelatin emulsion films
JPH0259517A (en) Steam and oxygen permeable adhesive bandage

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19890907

17Q First examination report despatched

Effective date: 19900823

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19920729

REF Corresponds to:

Ref document number: 78703

Country of ref document: AT

Date of ref document: 19920815

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3873275

Country of ref document: DE

Date of ref document: 19920903

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: ST. DR. CAVATTONI ING. A. RAIMONDI

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19921112

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19921130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2034260

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19931111

EAL Se: european patent in force in sweden

Ref document number: 88310610.6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19951016

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19951018

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19951020

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19961110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19961111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19961130

BERE Be: lapsed

Owner name: LANDEC LABS. INC.

Effective date: 19961130

EUG Se: european patent has lapsed

Ref document number: 88310610.6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19971130

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990601

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19990601

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20001120

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20001121

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20001122

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011130

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020702

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20021017

Year of fee payment: 15

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19941214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040730

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051110